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Abstract Advanced drug delivery systems (DDS) present
indubitable benefits for drug administration. Over the past
three decades, new approaches have been suggested for the
development of novel carriers for drug delivery. In this review,
we describe general concepts and emerging research in this
field based on multidisciplinary approaches aimed at creating
personalized treatment for a broad range of highly prevalent
diseases (e.g., cancer and diabetes). This review is composed
of two parts. The first part provides an overview on currently
available drug delivery technologies including a brief history
on the development of these systems and some of the research
strategies applied. The second part provides information about
the most advanced drug delivery devices using stimuli-
responsive polymers. Their synthesis using controlled-living
radical polymerization strategy is described. In a near future it
is predictable the appearance of new effective tailor-made
DDS, resulting from knowledge of different interdisciplinary
sciences, in a perspective of creating personalized medical
solutions.
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An overview in drug delivery systems
The introduction of drugs in human body may be
accomplished by several anatomic routes [1]. In order to
achieve the therapeutic purpose, the choice of the most
suitable administration route is of unquestionable impor-
tance. Therefore, several factors must be taken into
consideration when administrating a drug, namely its own
properties, the disease to be treated and the desired
therapeutic time. The drugs can be administrated directly
to the target tissue or organ or can be delivered by systemic
routes [2]. Systemic drug delivery routes are presented
systematically in Table 1.
Pharmaceutical treatments started plenty of decades, or
even centuries ago (e.g., aspirin since 1828) either with the
oral administration of solid pills (and liquids) [4], or with
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injectables active chemical drugs [5]. When either of these
methods is applied, drug dose maintenance in the body is
achieved by repeated administrations. Despite the effec-
tiveness of these treatments, dose peaks at administration
times alternated with sub-therapeutic drug levels are
unavoidable. Therefore, the impossibility of controlling
the drug level over a long period of time constituted an
important drawback. During the past two decades, new
approaches and strategies have been developed to control
several parameters considered essential for enhancing the
treatment performance such as the rate, period of time and
targeting of delivery. This was the beginning of the so
called drug delivery systems [3].
The main purpose of using a DDS is, as implied, not
only to deliver a biologically active compound in a
controlled manner (time period and releasing rate) but also
to maintain drug level in the body within therapeutic
window (Fig. 1). Besides, one can direct the drug towards a
specific organ or tissue (targeted drug delivery) [6]. The
first two features were addressed by using drug carriers,
usually polymers (either biopolymers or synthetic poly-
mers) which properties could be manipulated in order to
improve DDS efficiency.
Although both natural (Table 2) and synthetic polymers
(Table 3) are being used in the preparation of DDS, there
are some advantages that can be pointed to synthetic
macromolecules [7].
When the polymers are man-made, it becomes possible
to control some aspects of polymer structure that allows
producing tailor-made materials suitable to the desired
biological application [8]. Also, three-dimensional structure
as well as chemical composition can be controlled in order
to adjust materials properties and orientation of specifics
functional groups that can interact with the drug.
However, attention must be paid to molecular weight of
synthetic polymers which are not biodegradable. Since
biodegradation does not always occur, synthetic polymers
must be eliminated through renal excretion [9]. Therefore,
they should present a uniform molecular weight distribution
that fits under the threshold of renal excretion. As further
described in this paper, controlled/living radical polymeri-
zation is a very reliable and applied technology in order to
obtain well defined macromolecular structures with narrow
range molecular weights distributions [10].
DDS present several advantages. These include impor-
tant factors from decrease of drug side-effects to increased
patient compliance. However, DDS disadvantages are also
well-known, e.g., DDS final price among others. DDS main
advantages and disadvantages are summarized in Table 4.
Targeted drug delivery aroused the interest of the
scientific community and consequently has witnessed
tremendous developments over the last decade. The active
compounds targeting involves the conjunction of different
areas related to active compounds design, active com-
pounds carriers, biological systems, genetic approaches and
precise design of new molecules.
In order to improve the effectiveness of the existing
methods for drug delivery, several steps need to be
accomplished. The main goal is generically related to
deliver suitable active compounds at a desired target
without any sign of degradation during the whole process.
The development of a controlled delivery system that can
dose orally, being less expensive and less painful for the
patients and at the same time extremely effective consider-
ing a specific disease represents a final target for the
research community [11].
DDS must possess some features. The system should be
recognized by the specific target tissues [12]. In fact, the
delivering of the drug in a specific area of the body is
extremely important, in terms of lowering possible side-
effects of the active compounds, when enter non-targeted
organs and tissues. The polymeric carrier itself, once in the
Fig. 1 Scheme of the effect in drug concentration in the body when
using different administration methods (adapted from [6])
Table 1 Classification of systemic drug delivery routes (adapted from [3])
Anatomic routes for systemic drug delivery
Gastrointestinal systems
Oral
Rectal
Parenteral
Subcutaneous injection
Intramuscular injection
Intravenous injection
Intra-arterial injection
Transmucosal
Transnasal
Pulmonary (inhalation)
Transdermal
Intra-osseous
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targeting area should be able to control the drug administra-
tion by means of either a physiological or chemical trigger.
The design of a delivery system should be done in such a way
that it would be suitable for specific areas of the body, where it
could be degraded by environmental conditions e.g., pH of the
stomach or the presence of some enzymes [3].
Polymeric based DDS currently available can be
classified as four different categories: diffusion-controlled
systems, chemically controlled systems, solvent-activated
systems, and magnetically controlled systems [13].
Diffusion controlled systems enclose both reservoir and
matrix systems. The first type of system is based in a
polymeric membrane that surrounds a core containing the
drug, while the second type is based on a polymer matrix in
which the drug is distributed homogeneously. Drug release
is, in both cases, controlled by diffusion (Fig. 2). However,
attention must be paid to the resistance of the polymeric
membrane of the reservoir systems since its rupture would
cause an abrupt drug release [14].
Chemically controlled systems include polymer-drug
conjugates in which drug molecules are linked to a
polymeric backbone often by means of a spacer molecule.
Once inside the body the linkage between polymer carrier
and the drug is cleaved either by hydrolysis or enzyme
cleavage. Different types of biodegradable or hydrolysable
chemical linkages are used to attach the drug to the polymer
backbone (Fig. 3) [15].
These polymer-drug conjugates usually possess a trans-
port system which is responsible for directing of the
polymer to target organs or tissues (Fig. 4).
Another type of chemically controlled system is the one
that involves the use of biodegradable/bioerodible poly-
mers. The distinction between these two concepts is based
on how degradation occurs. The term biodegradation is
usually applied when polymer molecular weight decreases
(by chain cleavage, Fig. 5) while bioerosion is used when
the mass of the system diminishes in which case we can
have surface or bulk eroding polymers (Fig. 6) [16]. In both
cases the polymeric chains matrix disruption is the
responsible for the drug release. By controlling polymer
degradation rates it is possible to control drug delivery
kinetics.
Table 2 Molecular structures of natural polymers used in drug
delivery applications
 Polymers name
Collagen
Chitosan
Dextran
Cellulose
Alginic Acid
 Polymers structure
Table 3 Molecular structures of synthetic polymers used in drug
delivery applications
 Polymers name
 Poly(lactic acid)
 Poly(lactic-co-glycolic acid)
 Poly(ε-caprolactone)
 Poly(ethylene glycol)
 Poly(alkyl cyanoacrylates)
 Poly(methyl methacrylate)
 Polymers structure
EPMA Journal (2010) 1:164–209 167
Solvent activated systems can be controlled either by
swelling or by osmosis. Swelling controlled systems are
based on a hydrophilic polymeric crosslinked chain that is
able to absorb large amounts of water without dissolving.
This water uptake allows the drug inside the system to
diffuse outwards at a velocity that depends on the amount
of water that enters the polymeric matrix (Fig. 7).
Osmotically controlled systems relies on a device
containing a semipermeable membrane through which a
solvent without or with small amount of drug flows toward
a chamber in which the drug is contained [17]. The solvent
flow increases pressure inside the chamber containing the
drug and forces the exit of the drug though an orifice
present in the device (Fig. 8).
Finally, magnetically controlled systems have been
developed mostly by combining a polymer with magnetic
microparticles. Due to these magnetic properties, the
particles movement inside the body can be influenced by
an externally applied magnetic field. This specific force
combines with the hemodynamic force of the bloodstream
resulting in a final motion force. However, in order to
obtain an effective control over the particles movement, the
external magnetic force has to overcome the hemodynamic
force. Therefore, when in vivo application is desired, low
values of magnetic fields must be applied. For this reason,
materials with high magnetization at room temperature
must be used. Among these, the most applied ones are iron,
cobalt and nickel [18].
A quite used strategy in developing DDS using magnetic
particles is their association with a smart polymer [19, 20].
This type of polymers will be further discussed in this
paper, but one can advance that these polymers are sensitive
and respond to some external stimuli, such as temperature
and pH. The most studied of these smart polymers for drugs
delivery applications are the thermo-responsive polymers
since the temperature is an easily controlled parameter [21].
The most interesting point on using thermo-responsive
hydrogels combined with magnetic particles results from
Fig. 3 Biodegradable chemical linkages
Fig. 2 Drug diffusion profile for both matrix (a) and reservoir
systems (b)
Table 4 DDS advantages and disadvantages
DDS advantages
Extension of the duration of action and bioavailability of the drug
Minimization of drug degradation and loss
Prevention of drug’s adverse side-effects
Reduction of dosing frequency
Minimization of drug concentration fluctuations in plasma level
Improved drug utilization
Improved patient compliance
DDS disadvantages
Possibility of toxicity of the materials
Harmful degradation products
Necessity of surgical intervention either on systems application
or removal
Patients discomfort with DDS device usage
High cost of final product
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the ability of these same particles to produce heat because
of hysteresis energy loss when subjected to an external
magnetic field [22]. Therefore, it is possible to produce a
DDS that would be activated when a magnetic field is
applied externally causing this energy release from the
magnetic particles. This type of systems has been mainly
applied in cancer treatment by attaching specific antibodies
to their surface that allow a targeted delivery of the system
(Fig. 9) [23, 24].
In summary, advanced controlled DDS present indubita-
ble advantages for pharmacologically active compounds
administration. Owing to rapid advances in recent years, the
application of polymers to drug delivery has grown
noticeably. Different treatment methods aiming to control
several diseases are currently available while some are still
under development or even in researchers’ imagination.
Polymers in drug delivery systems
As already mentioned, DDS can be produced by using
natural or synthetic polymers, which can be biodegradable
or non-biodegradable (see Fig. 10).
These polymeric systems can be used in the release of
drugs, proteins and cells. The polymers used in DDS should
present a set of properties that make them suitable materials
to interact with the human body, as discussed in the
previous section, being the biodegradability one of the
most important features.
Biodegradable polymers are particularly attractive for
application in DDS since, once introduced into the human
body, they do not require removal or additional manipu-
lation. Their degradation products are normal metabolites of
the body or products that can be metabolized and easily
cleared from the body [25, 26].
Some natural polymers, being biodegradable and with
excellent biocompatibility, are very attractive materials for
use in DDS. Besides, they are relatively inexpensive.
However, some of them present some limitations, namely
antigenicity, risk of viral infection and non-uniformity in
the properties from batch-to-batch [25, 27].
Moreover, synthetic polymers offer a wide variety of
compositions with adjustable properties. These materials open
the possibility of developing new DDS with specific
properties (chemical, interfacial, mechanical and biological)
for a given application, simply by changing the building
blocks or the preparation technique. Since their preparation is
very reproducible, it is possible to prepare DDS with the same
specifications quite easily [25–27]. Synthetic polymers can
also be either biodegradable or non-biodegradable. Biode-
gradable synthetic polymers are those containing in their
polymer backbone linkages such as ester, orthoester, amide,
urea or urethane [26]. Thus, it is possible to increase
biodegradability of non-biodegradable polymers by intro-
ducing such moieties in their backbone.
Another possible strategy is the design of DDS com-
prising natural and synthetic blocks. The final purpose is to
gather in the same material the best properties of the natural
Fig. 4 Schematization of gener-
al structure of polymer-drug
conjugate
Fig. 5 Biodegradation of poly-
mer chains with consequent
drug release
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polymer (biodegradability and biocompatibility) and the
synthetic polymer (e.g., mechanical properties) [28, 29].
Natural polymers
Along this subsection, it is intended to give an overview of
the most currently used natural biodegradable polymers in
drug delivery devices. The source of the materials and some
of the main application as DDS are presented.
Proteins
As it is well-known, proteins are high molecular weight
compounds composed by amino acid residues, linked
together by peptide (amide) linkages. They are the main
structural components in human tissues. Among these,
collagen, gelatin and albumin have been used in the design
of DDS.
Collagen Collagen is the most abundant protein in the
human body, being the major component of skin, cartilage
and bone. This natural polymer is non-toxic, biodegradable
and low-immunogenic [30]. Collagen has been used in
DDS, in a variety of shapes, namely microspheres,
minirods and sponges [31].
Collagen microparticles have been tested as a carrier
system for glucocorticoids, namely hydrocortisone. It was
found that the release behaviour of this specific drug was
not influenced by the pH of the surrounding medium [32].
Collagen minirods (minipellets) were tested as delivery
systems for high-molecular-weight drugs [31]. As an
example, the work of Metzmacher and co-authors is
presented. They prepared an unsoluble and non-
crosslinked collagen minirod delivery system, using fluo-
rescein isothiocyanate (FTIC)-dextran as model drug. The
results showed that the release profile of the drug from
the matrix is a two step process being dependent on the
molecular weight of the drug and length of mini-rod [33].
Collagenous matrices (sponges) have also been used in the
sustained release of growth factors (e.g., vascular endothelial
growth factor, VEGF and fibroblast growth factor, bFGF), as
demonstrated by Kanematsu and co-authors [34].
Gelatin Gelatin is a protein obtained by the partial
hydrolysis of collagen. In this process, the collagen is
converted to an unoriented water-soluble protein. In
aqueous solution, gelatin undergoes a sol-gel transition,
when temperature is lowered below 35°C. This compound
being biodegradable, biocompatible and non-immunogenic
is commonly used in biomedical field (e.g., drug delivery
vehicles and wound dressings). Due to its high solubility in
water and poor mechanical properties, crosslinking of
gelatin with other materials may be necessary [35, 36].
Fig. 9 Drug loaded magnetic particle with specific antibodies
attached to the surface applied in cancer treatment
Fig. 8 Scheme of an osmotically controlled DDS
Fig. 7 Drug release resulting from swelling of a polymeric matrix
Fig. 6 Scheme representing surface (a) and bulk (b) bioerosion
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Muvaffak and co-authors prepared gelatin crosslinked
microspheres loaded with colchicine, an agent used in the
cancer treatment. They obtained high drug entrapment
efficiency and the release profiles were found to be
dependent on the gelatin and crosslinking agent concen-
trations [37]. In the same field of research, microspheres of
gelatin were used for the entrapment of some anti-cancer
drugs, namely doxorubicin [38], 5-fluoruoracil (5-FU),
bleomycin (BLM) and mitomycin C (MMC) [39].
Ofokansi and Adikwu used gelatin-mucin microspheres for
the delivery of cefuroxime sodium (a bactericidal agent) in the
rectal tract. The microspheres presented high drug entrapment
efficiency. However, a fast drug release was observed [40].
Gelatin based hydrogels have also been used in the drug
delivery of some active compounds like antibacterial
proteins. As an example, Kuijpers and co-authors used
gelatin and gelatin/chondroitin sulphate hydrogels, cross-
linked via a carbodiimide mediated reaction, impregnated
in Dracon® (poly(ethylene tereftalate) matrix), as delivery
system for antibacterial proteins. Lysozyme was used as a
model compound. The results showed an enhancement of
both lysozyme loading and sustained release time, with the
incorporation of chondroitin sulphate in gelatin hydrogels.
An in vivo experiment showed that these materials are well
tolerated by living tissues and are completely degraded in
18 days [41, 42].
Recently, Lin and co-authors proposed a novel drug
delivery system composed of poly(ε-caprolactone) (PCL)
particles embedded in a gelatin film, using ibuprofen as a
model drug. This system showed a prolonged sustained drug
release and an enhancement in the adhesion properties. This
system can be applied, for instance, in wound healing [36].
Albumin Albumin is the most abundant protein in the
human blood plasma. It is hydrosoluble and presents a
molecular weight of about 66 kDa [30]. Characteristics like
biodegradability, non-toxicity and non-immunogenicity,
makes albumin a very promising material for biomedical/
pharmaceutical applications, including drug delivery pur-
poses [43]. Albumin microspheres have proved to be a
suitable carrier for drugs used in cancer treatment [44]. This is
mainly due to the fact that albumin is used by cancer cells as
a source of nitrogen and energy, being taken up by tumor
cells by a mechanism of fluid phase endocytosis, followed
by lysosomal breakdown. With this mechanism, the drugs in
the albumin microspheres are delivery in the specific site of
action, minimizing systemic toxicity [43, 44]. Albumin
microspheres, loaded with anti-cancer drugs, have showed
to be efficient in breast cancer treatment [45, 46].
Polysaccharides
Polysaccharides are high molecular weight compounds, com-
posed by monosaccharide repeating units. They present a wide
range of properties and structures. The presence of reactive
lateral groups allows the modification of their structure, further
increasing their possible applications. Among these, chitosan,
alginate and dextran are widely used in DDS development.
Chitosan Chitosan is a cationic polysaccharide obtained by
the alkaline deacetylation of chitin (see Fig. 11), that is the
main constituent of the shells of marine crustaceans.
Fig. 11 Schematic representation of the alkaline deacetylation of
chitin to obtain chitosan
Fig. 10 Overview of the poly-
mers used in DDS
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It is insoluble in water and in organic solvents, but it can be
dissolved in mildly acidic solutions [47]. This polysaccharide
possesses high biodegradability, low toxicity and good
biocompatibility and, for that reason, it is widely used in
biomedical/pharmaceutical applications, namely in drug de-
livery devices with different shapes and geometries [47, 48].
Chitosan micro/nanoparticles are a widely used drug
delivery devices. Chitosan particles based on ionotropic
gelation method (Fig. 12) between sodium tripolyphospate
and chitosan were tested as drug carriers for proteins, using
bovine serum albumin (BSA) as model compound [49, 50].
The same kind of particles was also investigated as drug
carriers for ophthalmologic applications and the obtained
results showed that the chitosan nanoparticles are well
tolerated by the ocular surface tissues [51, 52]. This method
of preparation is very attractive, since it does not require
severe reaction conditions, thus maintaining the integrity of
the drug [49].
Chitosan particles prepared by the complex coacervation
method were used in the encapsulation of genetic material to be
applied in gene therapy, as it will be further discussed in this
paper. The system showed to be efficient in protecting the
genetic material from nuclease attack. The transfection effi-
ciency showed to be dependent on the molecular weight of
chitosan, concentration of nucleotide and type of cells [53, 54].
Hydrogels based on chitosan have been used as DDS in
the field of cancer treatment, as reviewed by Thu Ta and co-
authors. Different methods of preparation and crosslinking
agents were presented. Examples of entrapped drugs are
paclitaxel, doxorubicin and camptothecin [55].
Alginic Acid Alginic acid is a cationic polysaccharide
extracted from brown algae. This polysaccharide is a block
copolymer composed of two uronic acid units: β-D-
mannuronic acid and α-L-glucoronic acid (Fig. 13). Algi-
nate’s molecular weight can be higher than 500 kDa [27,
30]. Usually, this material is used in its sodium salt form.
Sodium alginate readily forms gels when in contact with
divalent cations (e.g., Ca2+), at ambient temperature. This
property is very important, since it opens the possibility of
encapsulating some active compounds, under mild con-
ditions, while maintaining their full biological activity [30].
Furthermore, sodium alginate is biocompatible and non-
immunogenic. However, it presents the disadvantage of not
being enzymatically degraded by mammals [30, 56].
Sodium alginate based hydrogels can be used for the
sustained and localized release of low-molecular drugs and
macromolecules. The release profile of the drug is
dependent on the interaction between the drug and the
biopolymer. The release profile of the active compounds
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Fig. 12 Schematic representa-
tion of the interaction of
chitosan with sodium
tripolyphospate
giving micro/nanoparticles
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can be adjusted by covalently crosslinking alginate with
other materials [56].
Angiogenic growth factors, like VEGF and bFGF, have
been entrapped in alginate microspheres. In these systems, a
fast initial release of the molecules was observed, and to
overcome the problem an alginate-heparin system, crosslinked
with ethylenediamine was developed. This DDS was designed
for specific application in tissue engineering field [57, 58].
Floating alginate beads have been also prepared and have
shown to be useful in the delivery of drugs in the
gastrointestinal tract [59].
Dextran Dextran is a polysaccharide of bacterial origin being
composed essentially by α-1,6-linked D-glucopyranose units.
It may present side branches in the positions α-1,2-, α-1,3- or
α-1,4 (Fig. 14) [60, 61].
It is an adequate material for biomedical applications due to
its biodegradability, biocompatibility, non-immunogenicity
and non-antigenicity [60].
Microspheres based on acrylated dextran, obtained by
reaction of dextran with glycidyl methacrylate (Dex-MA)
or hydroxyethyl methacrylate (Dex-HEMA), have been
used for the controlled release of proteins. These micro-
spheres present the advantage of being prepared in aqueous
medium [62]. In vivo experiments, performed in rats,
showed that these polysaccharide microspheres are well
tolerated when injected subcutaneously [63].
Casadei and co-authors developed a DDS for ibuprofen,
comprising solid lipid nanoparticles embedded in a Dex-
MA hydrogel, crosslinked by ultraviolet (UV) radiation.
This system permitted to obtain a percentage of drug
retention nearly 60%, after 2 h in acidic medium, with a
subsequent slow release in neutral medium. These results
indicate that this system is adequated for modified delivery
oral formulations of lipophilic drugs [64].
Recently, Raemdonck and co-authors evaluated the poten-
tial application of dextran-UV photopolymerized hydrogel
nanoparticles as a carrier for genetic material. The hydrogel
particles presented a high loading capacity. The citoxicity tests
done with a human hepatoma cellular line HuH-7 demon-
strated that these particles are slightly citotoxic. It was shown
that the efficiency of gene silencing depends on the
degradation profile of the nanoparticles. This can be modified
by changing the derivatization degree of dextran [65].
Recently, Horning and co-authors, prepared a prodrug
made from dextran and hydrophobic drugs (iboprufen and
naproxen), in a N,N′-carbonyldiimidazole mediated reaction
[60]. This prodrug is hydrophobic in nature and, when in
contact with water or water miscible solvents, self-assembles
into nanoparticles. These nanoparticles presented high load
efficiency and showed to be stable under pHs in the range of
4 to 11, for several months. This system seems to be reliable
for the sustained release of hydrophobic drugs.
Fig. 14 Molecular structure of dextran (adapted from [61])
Fig. 13 Alginate molecular
structure
EPMA Journal (2010) 1:164–209 173
Artificial polymers
Cellulose derivatives
Cellulose is the most abundant occurring biopolymer in the
nature. It is a linear polymer composed of β(1→4) linked
D-glucose units, each one presenting three hydroxyl groups.
These hydroxyl groups are responsible for the strong
intermolecular and intramolecular H-bonds that are estab-
lished between the cellulosic chains, making it insoluble in
water and organic solvents [66]. Thus, the chemical modifi-
cation of cellulose is necessary to spread the fields of
application of this polymer. Cellulose derivatives are also
biocompatible polymers with application in biomedical field.
Hydroxypropylmethylcellulose (HPMC) (Fig. 15) is a
cellulose ether widely used in the preparation of drug
delivery devices. When in contact with water or biological
fluids, this polymer becomes hydrated, leading to a
‘disentanglement’ of the polymeric matrix, forming a
swelling gel layer. It is accepted that the drug release from
a HPMC matrix comprises two steps: diffusion through the
swelling gel layer and release due to the erosion of the
swollen matrix [66, 67]. The drug release from this type of
matrices can also be influenced by viscosity of the gel layer
formed during the hydration of the polymer [66].
Along the years, HPMC has been used as carrier for several
drugs and the factors influencing the release behaviour have
been studied, as documented by Kamel and co-authors [66].
Recently, a HPMC-indomethacin (an anti-inflammatory
drug) composite was formulated by supercritical fluid (e.g.,
sc-CO2) assisted impregnation method [68]. The results
indicated that hydrogen bonding is the primarily form of
interaction between the polymer and the drug. Various
processing conditions were used: the HPMC-indomethacin
drug composite processed at 130°C and 17.2 MPa, presented
a drug release behaviour that obeyed to a n-power law
Mt=M1 ¼ Ktnð Þ, with n=0.54. This strategy is very inter-
esting and promising since it opens the possibility of
preparing natural drug carriers in a ‘green’ way [68].
Ethylcellulose (EC) (Fig. 16) is another cellulose
derivative used in DDS. EC is a non-ionic cellulose ether,
insoluble in water, but soluble in some polar organic
solvents. In the last years, EC has been used for the
controlled release of various types of drugs: diclofenac
sodium [69], ketoprofen [70], betamethazone [71] and more
recently, nimesulide [72]. In these contributions, some
parameters like drug and polymer concentration or type of
solvents were evaluated in order to get improved delivery
systems based on this polymer.
Synthetic polymers
Along this section, the most common synthetic polymers used
in drug delivery devices will be described. As stated above,
this kind of polymers offer the great advantage of being
synthesized with specific properties for a given application.
Biodegradable synthetic polymers
Polyesters Poly(lactic acid) (PLA), and poly(lactic co-glycolic
acid) (PLGA) (Fig. 17) are the most widely used polymers in
drug delivery devices. This fact can be attributed to their
biodegradability, biocompatibility, low-immunogenicity
and low-toxicity [26]. A tailored degradation rate of these
copolymers can be achieved only by varying the stereo-
chemistry (D or L-lactic acid monomer) and the PLA/PGA
(poly(glycolic acid)) ratios [27]. PLGA, due to its higher
degradation rate comparatively to PLA, is sometimes the
preferred polymer for drug delivery devices.
Micro/nanoparticles of PLGA have been used in the
controlled delivery of proteins, vaccines, genes, antigens as
well as growth factors. An excellent review on this matter
was done by Mundargi and co-authors [73]. These particles
Fig. 17 Structures of poly(lactic acid) and poly(lactic co-glycolic acid)
Fig. 16 Ethylcellulose structure
Fig. 15 Hydroxypropylcellulose
structure
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are also suitable for the encapsulation of anti-cancer drugs
[74]. Several studies have been done on the influence of
certain parameters (presence or absence of stabilizers in the
formulations [75], type of solvent [76] and molecular
weight of the drug [77]) in the encapsulation efficiency or
drug release profiles from these micro/nanoparticles.
This kind of micro/nanoparticles has demonstrated their
potential for application in gene delivery. PLGA particles
and a mixture of PLGA particles with polyoxyethylene
derivatives were used in the encapsulation of genetic
material. These systems have proved to be efficient in
protecting the genetic material from the nuclease attack and
high transfection efficiencies were obtained [78, 79]. A
cationic complex of PLGA with polyethyleneimine was
also used in the encapsulation of genetic material. It was
shown that, in this particular case, the gene silencing
mechanism is performed at the intracellular level [80].
A study done by Kompella and co-authors showed that
PLA and PLGA nanoparticles have potentialities for the
design of gene therapy strategies for ocular diseases of the
posterior segment of the eye.
PCL (Fig. 18) is a semicrystalline polymer with low
melting point (Tm=55–60°C) and glass transition temper-
ature (Tg=−60°C). It possesses a low degradation rate,
reason why it has been mainly used for preparation of
long-term drug delivery devices [25]. PCL is highly
permeable to small drug molecules. Another important
feature is related to the non-generation of acidic by-
products when it is degraded (contrarily to what happens
with PLA and PLGA). Additionally, PCL offers the
possibility of being easily blended with other polymers [81].
PCL, in its native form or blended with other polymers
has been used for the encapsulation of several drugs, as
reviewed by Sinha and co-authors [81] and more recently
by Kumari and co-authors [74].
Poly(ortho esters) The development of poly(ortho esthers)
(POE) is related with the necessity of having more
hydrophobic polymers, containing hydrolytically labile
chemical bonds, with a surface erosion degradation mech-
anism instead of a bulk degradation mechanism [25, 30].
Currently, four families of POE are known: POE I, POE II,
POE III and POE IV. POE I is obtained by transesterifica-
tion reaction between a diol and a diethoxytetrahydrofuran.
POE II is synthesized from diols and diketene acetal 3,9-bis
(ethylidene 2,4,8,10-tetraoxaspiro[5,5] undecane). This
polymer is highly hydrophobic. Usually, it is necessary
the addition of an acid excipient to make it appreciable
degradable under physiological conditions. POE III can be
obtained by a reaction between a triol and an ortho ester.
The flexibility of the polymer backbone can be easily
tailored by the selection of the triol. POE IV is a modification
of POE II; in this specific case units of lactic acid or glycolic
acid are incorporated in the polymer backbone, which
enables the degradation of these polymers, without the
addition of acidic excipients. Besides, the rate of degradation
of these polymers can be tuned by the amount of lactic or
glycolic acid present along the polymer chain [25, 30]. The
structures of the mentioned POEs are presented in Fig. 19.
POE IV presents a number of advantages over the other
POE families, namely the possibility of controlling the
polymer properties and erosion rate, high stability at room
temperature and drug release dependent on erosion mech-
anism [82]. Thus, POE IV seems to be the most adequate
drug carrier for a variety of drugs, including proteins, in
diverse applications, as well documented by Heller who
described various types of DDS based on POE [82–84].
Poly(alkylcyanoacrylates) Poly(alkyl cyanoacrylates)
(PACA) (Fig. 20) are biodegradable acrylate polymers,
with a wide range of applications in the biomedical/
pharmaceutical field. Their C-C bonds are hydrolytic
instable, which can be ascribed to the high inductive
activation of methylene hydrogen atoms by the electron-
withdrawing neighboring groups [25].
PACA exhibit high rates of degradation that can vary
between hours and days, depending on the alkyl (R)
chain length of the polymer. For instance, poly(methyl
cyanoacrylate) can degrade within a few hours, but its
degradation products (cyanoacetic acid and formalde-
hyde) are toxic to the organism. Therefore, the research
has been directed towards PACA with longer alkyl chains
[25, 30].
The development of PACA particles for drug delivery
purposes has started two decades ago [85]. Almost all type
of drugs have been successfully encapsulated in PACA
particles (microparticles, nanoparticles or capsules). Among
them, peptides, proteins, oligonucleotides, anti-cancer and
anti-infectious compounds as well as anti-inflamatory
compounds are included [74, 85]. A comprehensive review
on the methods of preparation, potential applications, and
drugs commonly incorporated was done by Vauthier and
co-authors [85]. Recently, Graf and co-authors reviewed
the methods of preparation, the factors influencing the
encapsulation efficiency and the drug release profiles.
They also presented results of some experiments done in
vivo [86].Fig. 18 Structure of poly(ε-caprolactone)
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Non-biodegradable synthetic polymers
Acrylic Polymers Poly(methyl methacrylate) (PMMA)
(Fig. 21), a biocompatible and biostable polymer, was the
first acrylic polymer used in a biomedical application.
PMMA is transparent, does not absorb water being
dimensionally stable. Its first biomedical application was in
intraocular lens (IOL), just after the Second World War.
PMMA is still used in the fabrication of contact lenses [27].
Besides the use of PMMA based materials in ophthal-
mology, it can also be applied in the orthopedic field;
PMMA has been used over 20 years in managing, for
example, open fractures, total joint arthroplasty and chronic
osteomyelitis. However, some of the applications have been
impaired by its bio-inertness and, for this reason, it was
proposed the addition of bioactive glasses/ceramics fillers.
The work of Lin and co-authors is an example of that. They
prepared a PMMA/silica composite via a sol-gel method
and tested it as a drug delivery device for anti-inflammatory
drugs, using acetylsalicylic acid as model drug. The
obtained results showed that interface between polymeric
matrix and silica particles plays a key role in drug release
behaviour, that demonstrated to be well fitted by the Ficks’
law [87]. PMMA can also be used in orthopedic surgery as
an efficient delivery device of anti-microbial agents, as
shown by Anguita-Alonso and co-authors [88].
A PMMA microdevice (flat and thin, in order to
maximize the area of contact), coated with lectins was
successfully used in delivering of drugs to the gastrointes-
tinal tract [89].
PMMA is a versatile biocompatible polymer with
applications as DDS in various areas of the biomedical field.
Poly(2-hydroxyethyl methacrylate) (PHEMA) possesses
a similar structure to PMMA (Fig. 22). The pendant
methylester group in PMMA is substituted by a pendant
hydroxyethyl ester group [27].
PHEMA is a biostable polymer, with the ability of forming
hydrogels. It is a particularly interesting polymer due to its
properties which can be easily manipulated, offering the
possibility of having tailor-made materials for specific
applications. The use of PHEMAbasedmaterials in controlled
release applications is well known [90, 91]. In some cases,
PHEMA delivery systems present an initial drug ‘burst
release’: immediately after being hydrated. Therefore, some-
times, it is necessary to proceed to structural modifications.
In a very recent work, Anderson and co-authors [92]
developed a drug delivery device for the release of
norfloxacin based on PHEMA, which surface was hydro-
phobized by the reaction with octadecyl isocyanate. This
system showed to be adequate in the prevention of post-
operative infection (endophthalmitis), after a cataract surgery.
Other areas of the biomedical field have been accessed
by PHEMA drug carriers, namely cancer treatment [91, 93]
and neurologic diseases treatment [94].
Fig. 20 Structure of poly(alkyl cyanoacrylates); R is an alkyl chain of
variable length
Fig. 19 Structures of the different families of poly(ortho esters): a POE I; b POE II; c POE III and d POE IV
Fig. 21 Structure of poly(methyl methacrylate)
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Acrylic polymers with pendant acidic (poly(acrylic
acid)) and N-substituted acrylamide polymers (poly(N-
isopropylacrylamide) (PNIPAAm)) are particularly interesting
for drug delivery purposes, since they are stimuli-responsive
materials [95]. The potential application of these polymers in
DDS will be appropriately discussed in the following
sections of this paper.
Responsive polymers
Introduction
Most of polymer-based DDS are hydrogels. Hydrogels are
three-dimensional high-molecular weight networks composed
of a polymer backbone, water and a crosslinking agent. They
are polymeric materials that do not dissolve in water at
physiological temperature and pH. Hydrogel are capable of
absorbing water without undergoing dissolution due to their
chemical structure which include hydrophilic functional
groups such as –OH, –COOH, –CONH2, and –SO3H. Being
insoluble, these three-dimensional hydrophilic networks can
retain a large amount of water that not only contributes to
their good blood compatibility but also maintains a certain
degree of structural integrity and elasticity [96].
Hydrogels can be classified according to several different
criteria depending on their preparation method and physico-
chemical properties. Table 5 shows some of these criteria.
Hydrogels can be prepared from natural or synthetic
polymers [97]. On the other hand, they can be classified
according to the nature of the crosslinks as chemical gels
(when three-dimensional network is achieved by permanent
covalent bonds usually achieved by using crosslinking agents)
or as physical gels (formed by the growth of physically
connected aggregates). Depending on the nature of the gelling
system, in the physical gels, the connections can be achieved
via hydrogen bonds, crystalline regions, ionic clusters, or
phase-separated microdomains [98–100].
The synthesis and development of polymeric based
materials that are able to respond to external conditions
enhance even more the importance of polymers in DDS. The
development of stimuli-responsive polymers is a broad area
that has been attracting interest in the scientific community.
Responsive polymers are materials that can undergo abrupt
changes that result from small variations in environmental
conditions, such as: temperature, pH, electric charges, ionic
strength, electromagnetic radiation, UV/visible light, ionic or
metallic interactions or combinations of them. These stimuli
can lead to different types of responses, such as degradation,
drug release, dissolution/precipitation, swelling/collapsing.
Figure 23 illustrates different types of stimuli and possible
response from polymers. Table 6 presents some polymeric
materials and the external stimulus that they are sensitive to.
Although all of the previous stimulus has been studied in
DDS, most of the works reported in the literature are related
to temperature and pH stimulus [96, 103–105]. The main
reason for that can be understood by the fact that variations
in pH and temperature are easily found in the human body,
e.g., fever, diseases or local infections. The deviations from
normal values can work as a trigger for reversible phase
transitions. The response of hydrogels to external stimulus
is evaluated considering different aspects, such as: material
change of shape, speed of response, viscoelastic behaviour
and shape recovery.
Gels exhibiting a phase transition in response to change
in external conditions such as pH, ionic strength, temper-
ature and electric currents are known as “stimuli-respon-
sive” or “smart” gels [6]. Thus, hydrogels have been
developed as stimuli-responsive materials, which can
undergo abrupt volume change in response to small
changes in environmental parameters, as schematically
shown in Fig. 24. Here, a drug is released when the
material (hydrogel) is submitted to a specific stimulus.
Fig. 22 Structure of poly(2-
hydroxyethyl methacrylate)
Table 5 Criteria and classification of hydrogels
Criteria Classification
Origin Natural
Synthetic
Water content Low swelling
Medium swelling
High swelling
Porosity Nonporous
Microporous
Macroporous
Superporous
Crosslinking Chemical (or covalent)
Physical (or non-covalent)
Biodegradability Biodegradable
Nondegradable
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Synthesis of stimuli-responsive polymers by conventional
methods
Several methods can be used to synthesize hydrogels.
However, most hydrogels are prepared by radical copolymer-
ization [106], graft copolymerization [107], chemical or
physical crosslinkage [108, 109] and ionizing radiation [110].
As represented in Fig. 25, chemical hydrogels are
usually synthesized by polymerizing a water-soluble mono-
mer (acrylic acid, acrylamide, hydroxypropylacrylate) in
the presence of a bi- or multifunctional crosslinking agent.
Another method to obtain a chemical hydrogel is, by
chemical reaction, crosslink the functional groups of a
water-soluble polymer. These functional groups can be
either vinyl groups, hydroxyl groups, amine groups or
carboxylic groups [101, 111].
Physical gels are prepared by crosslinking without
chemical reaction. They are formed by the growth of non-
covalent bonds, which are formed through hydrogen bonding,
electrostatic interactions, ionic clusters, antigen-antibody
interactions and crystalline regions [100, 101]. These phys-
ically crosslinked gels can reversibly degrade into the
corresponding precursors upon external stimuli [112].
Physical hydrogels present polymeric network composed
by hydrophilic and hydrophobic domains, whereas chemical
hydrogels present “clusters” or regions of high crosslinking
density (which induce a high swelling structure) [113].
Smart polymeric materials respond to small changes in
their environment with significant changes in their properties.
As previously mentioned, several stimuli have been
exploited, although most of the works have been related with
temperature or pH stimuli. Ideally, the response to the stimuli
should be reversible. This fact makes chemical crosslinked
hydrogels good candidates to be used in drug delivery
applications due to their good mechanical stability [103, 105].
Temperature-responsive polymers
Temperature sensitive (or thermosensitive) hydrogels are
among the most studied class of stimuli-responsive poly-
mers for drug delivery systems.
Temperature sensitive polymers present an hydrophobic–
hydrophilic balance in their structure and small temperature
changes around a critical solution temperature (CST)make the
chains collapse or extend, responding to adjustments of the
hydrophobic and hydrophilic interactions between the poly-
mer chains and the aqueous medium [114, 115]. A critical
solution temperature can be defined as a temperature at
which the polymer solution undergoes separation from one
phase to two phases. Thus, temperature sensitive polymers
undergo an abrupt change in volume as the temperature of
the medium is varied above or below the CST [116].
Temperature is the most used triggering signal for DDS,
which in principle, can be justified by the fact that the human
body temperature frequently deviates from the normal value
(37°C) in the presence of strange microorganisms. The idea to
have a device able to recognize this deviation and at the same
time release a therapeutic agent is particularly interesting. In
terms of physical-chemical changes the thermoresponsive
hydrogels can involve swelling effects, glass transitions,
crystalline melting and thermally reversible transitions.
The temperature sensitive hydrogels are able swell/
deswell as a result temperature changes in the environmen-
tal medium. According to Peppas and co-authors [117]
these materials can be classified into negatively thermo-
sensitive, positively thermosensitive and thermally revers-
ible gels. Table 7 summarizes the most important features
of each category.
PNIPAAm hydrogels are typical examples among the
temperature sensitive polymers. PNIPAAm gels swell when
Fig. 23 Stimuli and polymer responses (adapted from [13, 101])
Table 6 Name of polymers and type of stimuli (adapted from [98,
101, 102])
Responsive polymer materials Type of
stimulus
Bisacrylamide pH
Poly(acrylic acid)
Chitosan
Poly(acetoacetoxyethylmethacrylate)
Poly(acrylamides)
Poly(butyl acrylate)
Poly(2-(diethylamino)ethyl methacrylate)
Poly(2-(diisopropylamino)ethyl methacrylate)
Poly(ethylene oxide) Temperature
Poly(N-isopropylacrylamide)
Poly(propylene oxide)
Poly(dimethylsiloxane) Electrical,
temperaturePoly(2-(methacryloyloxy)ethyl phosphorylcholine)
Poly(N-isopropylacrylamide)-co-acrylamide
containing ferromagnetic material
Magnetic
Poly(N-vinylcaprolactone) Temperature,
pHPoly(N-acryloyl-N-propylpiperazine)
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cooled below their lower critical solution temperature
(LCST) around 31–34°C, and they collapse when heated
above the LCST.
In earlier studies, Shibayama and co-authors [121–123]
have shown that, in a swollen PNIPAAm gel, there are two
types of water molecules association. About 10 to 15 water
molecules per NIPAAm segment are associated with the
phase transition, while about 1 to 3 water molecules per
polymer segment may be considered as the lower limit for
the hydrophobic hydration. The water molecules in the
hydration layer are in an ordered state if the temperature is
lower then the LCST. However, if the temperature is above
the LCST, water molecules are dissociated.
The concept of drug delivery via temperature sensitive
hydrogels can be illustrated according to Fig. 26. In
Fig. 26a an hydrophilic drug is trapped in a swollen gel
and once the temperature decreases below the LCST the
drug is released due to the increase of diffusivity. In
Fig. 26b, an hydrophobic drug is release from the matrix
when temperature is above LCST. In Fig. 26c, the drug is
trapped in the gel due to its heterogeneous nature which
above the LCTS form a dense layer while the core remains
swollen [105, 124].
Kikuchi and co-authors [125] grafted the thermo-
responsive PNIPAAm arms onto an inert hydrogel matrix.
This allowed a fast responding PNIPAAm hydrogel that can
avoid the skin layer formation upon rapid temperature
change.
Recently, highly deformable red blood cells were incorpo-
rated either between PNIPAAm gel and cover glass or
patterned PNIPAAm gel by Pelah and co-authors [126]. When
the temperature was increased above the LCST of PNIPAAm,
the polymer gel shrinks, which causes the deformation of the
embedded cells. The deformation of cells can be transformed
into biochemical responses, which play critical roles in cell
development, migration, and morphology [126].
pH-responsive materials
The pH changes within the body can be used to induce a
response since different organs or tissues have different and
specific pH. Table 8 shows the different pH of some organs
or tissues within the human body.
The presence of ionisable weak acid or basic moieties
attached to a hydrophobic backbone of the material is the
key element for a pH sensitive polymer. Once the side
groups are ionized, an extension of the coiled chains occurs
in response to electrostatic repulsion of the generated
charges formed, which can be either anions or cations.
Schmaljohann [13] showed that the extent of ionization
of the pH sensitive polymers depends on the concentration
of the pendant acidic/basic groups. All the pH sensitive
Fig. 25 Methods for the
synthesis of hydrogels (adapted
from [101])
Fig. 24 Schematic representation of a stimuli-responsive hydrogel
releasing a drug. The predictive transition behaviour of responsive
polymers is explained by the readjustment of interactions between
polymer-polymer and polymer-solvent in small ranges of pH or
temperature. Depending on the polymer structure the stimulus can
lead to an abrupt volume change
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hydrogels contain pendant basic or acidic groups that are
able either to accept or donate protons in response to the
environmental pH.
To obtain a pH-responsive polymer, monomers like
acrylic acid (AA), methacrylic acid (MAA), maleic anhy-
dride (MA), and N,N-dimethylaminoethylmethacrylate
(DMAEMA) are normally used [111]. Polymers containing
phosphoric derivatives have been also reported [99].
The swelling and collapsing behaviour induced by a pH-
responsive stimulus has been used in controlled release of
compounds like caffeine, drugs like indomethacin, or
cationic proteins like lysozome [13].
Poly(acrylic acid) has been widely used as a pH-
responsive polymer. The carboxylic pendant groups of its
chain, as shown in Fig. 27, accept protons at low pH, while
releasing them above its pKa (4.28) [127]; therefore the
corresponding hydrogels made with this system will exhibit
a sudden increase in the hydrodynamic volume and in the
swelling capability when the repeating units pass from a
ionized to a deionized state. When a basic polymer is used,
e.g., poly(N,N′-diethylaminoethylmethacrylate), the oppo-
site effect is observed (Fig. 28).
Polysaccharides can also be used as pH-responsive
hydrogels. Examples of anionic natural macromolecules
are alginate, hyaluronic acid and chondroitin sulphate. On
the other hand, only chitosan is a cationic natural
polysaccharide [105].
Other studies, which can again be used in drug delivery,
have been also performed with micro/nanogels. Mainly, the
immobilization of hydrolytically sensitive molecules like
peptides and proteins has been accomplished, e.g., van
derWeert and co-author [128] immobilized lysozyme in
PLGA, and Peppas and co-authors [117] prepared anionic
pH-sensitive hydrogels for calcitonin entrapment.
Temperature/pH-responsive materials
The combination of a thermo-responsive monomer (e.g.,
NIPAAm) and a pH-responsive monomer leads to a double-
response copolymer. Temperature/pH-dual-responsive systems
may have potential applications in the development of new
anti-cancer drug delivery systems, since certain malignancies
can alter simultaneously the two parameters around the tumor
place, including a slight local increase of the temperature and a
minor decrease in extracelular pH.
Ganorkar and co-authors [129] used temperature/pH-
sensitive copolymers—Poly(NIPAAm-co-butyl methacrylate-
co-AA)—to prepare insulin releasing. At acid pH and body
Fig. 26 Drug delivery strategies from temperature-responsive hydro-
gels (adapted from [124])
Table 7 Classification and characteristics of the different thermosensitive materials
Classification Characteristic Transition Example T (°C) Ref
Negatively
thermosensitive
Lower critical
solution temperature
(LCST)
Below LCST the
polymer swells,
above the polymer
contracts
NIPAAm 32°C in
pure water
[118]
Positively
thermosensitive
Upper critical solution
temperature (UCST)
Below UCST the
polymer contracts
Poly(acrylamide-co-butyl methacrylate) [119]
Thermally
reversible gels
Gelation temperature Liquid to a gel Poly(ethylene glycol-b-poly(lactic acid-
co-glycolic acid)-b-poly(ethylene glycol)
[120]
Tissue/ organ pH
Blood 7.35–7.45
Stomach 1.0–3.0
Duodenum 4.8–8.2
Colon 7.0–7.5
Early endosome 6.0–6.5
Late endosone 5.0–6.0
Lysosome 4.5–5.0
Tumor 6.5–7.2
Table 8 pH in the different
tissues (adapted from [13])
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temperature, the beads were insoluble, and thus no drug was
released in the stomach. At pH 7.4 and body temperature, the
low-molecular weight hydrophilic polymeric beads displayed
a hump-like profile and dissolved within 2 h (inducing a
controlled release mechanism), while the high-molecular
weight hydrophilic polymeric beads swelled and released
insulin slowly over a period of 8 h.
More recently, Asoh and co-authors [130] prepared gels
with porosity by combining poly(acrylic acid) with porous
PNIPAAm. These gels exhibited a faster deswelling in
response to both pH and temperature, when compared with
the corresponding nonporous gels.
UV and visible light sensitive materials
Light sensitive hydrogels include UV and visible light
sensitive hydrogels. These polymer gels go through
reversible photomechanical changes when exposed to UV
or visible light.
UV sensitive hydrogels bearing triphenylmethane units
swell in the presence of UV light and contract when the light is
removed. However this volume transition is discontinuous.
In a study of Qiu and co-authors [131], visible light-
sensitive hydrogels were prepared using copper chlorophyll
bound to NIPAAm, which shrinks, in response to visible
light and contracts when the light source is removed. This
material may be used in artificial muscles, switches, and
memory devices. However, response time is slow and
chlorophyll can get leached out of the polymer matrix.
Electric-responsive materials
Kim and co-authors [132] synthesized an hydrogel com-
posed of poly(vinyl alcohol) (PVA) and chitosan which
exhibited electro-sensitive behaviour. They investigated the
response of the hydrogel in electric fields. A swollen PVA/
chitosan network was placed between a pair of electrodes
and bending behaviour in response to the applied electric
field was noted. The bending angle and the bending speed
of the PVA/chitosan interpenetrated network (IPN) in-
creased with increasing applied voltage and concentration
of NaCl aqueous solution.
Synthetic as well as naturally occurring polymers either
alone or in combination, have also been used. Examples of
naturally occurring polymers include hyaluronic acid,
chondroitin sulfate, agarose, xanthan gum and calcium
alginate. The synthetic polymers are mostly methacrylate
and acrylate derivatives such as partially hydrolyzed
polyacrylamide, polydimethylaminopropylacrylamide,
among others.
Tanaka and co-authors [134] were the first authors to
explain the electrically induced anisotropic gel deswelling.
They suggested that a force on both the mobile counter ions
and the immobile charged groups of the gel’s polymeric
network is generated by the electric field. When the gel is
not fixed to either electrode, the attractive forces between
the immobile negative charges of the polymer network and
the anode can result in translational movement of the gels
towards the anode.
In a recent study, Bajpai and co-authors [134] impreg-
nated polyaniline into a macromolecular matrix of poly
(vinyl alcohol)-g-poly(acrylic acid) and studied the electri-
cal conductivity and electroactive behaviour of the resulting
nanocomposite.
Magnetic-responsive materials
Living organisms are deeply influenced by magnetism. The
iron-containing protein in our blood (hemoglobin) is magnet-
ic. Blakemore and co-authors [135] found that magnetotactic
bacteria were perhaps the first living organisms to orient
themselves with the earth’s magnetic field. A work from
Bahadur and co-authors [136] showed that all living
organisms, including animals and humans, contain magnetic
particles that act as magnetic receptors. Several researchers
[137–140] have established that magnetism and magnetic
materials have strong importance in healthcare and biological
applications, such as gene and drug delivery, and magnetic
intracellular hyperthermia treatment of cancer.
Cancer treatment by electromagnetically heating was
studied by Rabin [141]. Cancer cells can be clinically
heated either by ultrasound, radio frequency, thermal
radiation, lasers or magnetic nanoparticles. These particles
are subjected to an oscillating electromagnetic field so they
can act like heaters. Thus, the application of a magnetic
field produces a directional force on each magnetic particle.
As the magnetic field oscillates at high frequency, the
average force on the particle is zero. The energy of the
Fig. 28 Poly(N,N′-diethylaminoethylmethacrylate) behaviour in
aqueous solution at low and high pH
Fig. 27 Poly(acrylic acid) behaviour in aqueous solution at low and
high pH
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oscillation is converted into heat, raising the temperature of
the nanoparticles and their biological material.
Synthesis of stimuli-responsive polymers
by controlled/living radical polymerization for DDS
Controlled/Living Radical Polymerization (CLRP) provides
a powerful route for the preparation of macromolecules
with controlled properties, such as: molecular weight,
narrow molecular weight distribution, uniformity, topology,
composition, architecture and functionality [142].
The precise synthesis opens unprecedented possibilities
to synthesize targeted tailor-made polymers for DDS. The
preparation of well defined copolymers based on stimulus-
responsive polymers that can be pre-assembled to macro-
structures with controlled morphologies is also extremely
relevant to enhance the efficiency of drug releasing. In the
same way, natural polymers and synthetic polymers can be
covalently linked to afford new bioconjugates [143–145].
The covalent attachment of controlled synthetic polymers
with well defined structures to biological entities such as
nucleic acids, proteins, carbohydrates, virus and cells
represents the combination of two fascinating worlds.
In the last decade, great progress has been made on
the development of controlled/living radical polymeriza-
tion methods [10, 142, 146–148]. The most successful
CLRP methods are the stable free radical polymerization
(SFRP), atom transfer radical polymerization (ATRP) and
degenerative based methods such as reversible addition
fragmentation transfer (RAFT) and iodine transfer (IT)
(Fig. 29).
The SFRP [142] uses stable radicals which reversibly
react with active radicals together forming dormant cova-
lent species. Several stable radicals have been successfully
used to control the radical polymerization. The most used
nitroxide is the (2,2,6,6-tetramethylpiperidinyl-1-oxyl
(TEMPO)) [149].
RAFT [150] and Degenerative Chain Transfer (DCT)
(also known as Degenerative Transfer (DT)) [151, 152] use
a chain transfer agent that reacts reversibly with the
propagation macro-radical. This reaction between the dormant
species and the active radicals results in the transfer of an end-
group from the transfer-agent to the radical. For the DT
process, this transfer directly involves, for example, an
iodine atom. In the RAFT process, an addition-
fragmentation process is used to exchange a moiety (for
Fig. 29 General schemes of the
most used LRP methods:
(1) SFRP; (2) RAFT/DT and
(3) ATRP
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example, a dithioester) between the two chains [153]. The
macromolecular design via the interchange of xanthates
(MADIX) process is similar to the RAFT process but uses
xanthates as transfer-agents [154]. For the RAFT approach,
generically the conventional initiators are used as radical
source.
Among the various CLRP methods, the ATRP is most
studied due to its simplicity, efficiency, high functional
tolerance and the fact that most of the initiators and
catalysts are available commercially.
The mechanism presented in Fig. 29 consists in the
formation of active radicals through a redox process catalyzed
by a transition metal complex. The Pn ● are known as
propagation radicals, while the Pn−X are defined as dormant
species. The transition-metal complex (Mnt  Y=Ligand)
plays an indispensable role in this system, since it provides
the activation and deactivation processes, which keep the
concentration of radicals to be very low. These processes are
related to a one-electron oxidation with concomitant abstrac-
tion of a (pseudo)halogen atom X from the dormant specie
(Pn−X) (n=0, initiator) [155]. The radicals (Pn ●) are able to
react reversibly with the oxidized metal complex (X−Mtn+1 /
ligand) to form again the dormant species and the activator.
The ligand is essential to the solubilization of the transition
metal salt in the organic medium and to the adjustment of the
redox potential of the metal center, which defines the
reactivity and the dynamics of the atom transfer process
[155]. Once the radicals are active, the polymer chain
growing process is similar to the free radical polymerization
(FRP) process. The equilibrium between the active species
and dormant species is shifted towards the dormant species
via an excess of the higher oxidation state of the catalyst that
is generated by a small amount of radical dimerization, during
the initial steps of polymerization. This effect is known as the
persistent radical effect (PRE) [156]. Several metal catalysts
have been proposed as mediators of the ATRP process.
Among these the copper based catalysts are extensively [157]
studied due to their potential, low cost and large availability.
New ligands for several transition metals have been devel-
oped with outstanding results achieved, related to the increase
of the catalyst activity (10,000 fold when compared to the
initial systems) [158]. In the last decade, the accomplished
developments with respect to the capacity to polymerize
different monomers and the smoothing of reaction conditions
for CLRP methods are remarkable. The different strategies
exploit the equilibria between growing radicals and dormant
species and minimize the proportion of terminated chains in
radical polymerization. However, the key point for the control
is that the number of chains is much greater in CLRP than in
FRP, therefore the rate of termination per chain is much lower
in CLRP [158].
Nevertheless, each CLRP technique has its advantages
and disadvantages. A complete description of kinetics,
controlling agents, kinetis, monomers, ligands, reactions
conditions and synthetic approaches is far beyond the scope
of this manuscript. There are a couple of comprehensive
reviews about different aspects of CLRP methods [10, 142,
146, 147, 153, 155, 158–166].
The controlled synthesis of block copolymers that can
self-assembled, leading to nanostructures, is of great
potential for the conception of new drug delivery carriers.
The possibility to introduce targeting residues (e.g., protein,
peptides and antibodies) on the surface of the nanocarriers
will make possible the delivery of the drug in specific
regions and cells.
The control at the molecular level will allow tailoring
relevant nanoscale features. It is possible to use block
copolymers that undergo reversible conformational changes
in response to external stimuli (pH, temperature, ionic
strength among others). These block copolymers can form
micelles and vesicles just by changing the environmental
conditions. For that reason, the synthesis of diblock,
triblock and star architecture has been focus of special
attention due to their self-assembling potential in aqueous
solution.
Under the scope of this manuscript, below it is presented
some important and representative references for the
development of new macromolecules with potential appli-
cation as DDS.
The control over the structure is of prime importance to
generate precise self-assembled nanostructures with con-
trollable features. The block lengths affect a couple of
parameters, like critical micelle concentration, stability,
morphology, hydrodynamic size, chemical functionalities
in the micelle corona and core. The available functionality
at the micelle corona and core is particular important for
further modification involving the crosslinking as route to
stabilize the supramolecular structure via covalent linkage,
and the conjugating with biological entities such as
targeting molecules (e.g., antibodies, folic acid and so on)
and therapeutics.
Self assembly (polymeric micelles and surfactants)
Stimuli responsive polymers are key elements in the design
of controlled drug delivery systems. Frequently, the stimuli-
responsive DDS are designed as “smart micelles”. These
structures are formed through self-assembly of amphiphilic
copolymers in a solvent that has no affinity for one of the
moieties. When the micelles are prepared in water a
hydrophobic core is shielded from the solvent by a
hydrophilic shell [167–169]. The synthesis of amphiphilic
block copolymers as building block of nanocarriers
(micelles/vesicles/micro-nanoparticles/capsules) for poten-
tial drug delivery applications is being a topic of great
attention by the scientific community.
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Block copolymers composed of hydrophilic and hydro-
phobic segments, depending on their structures and
compositions, will self-assemble in solution to form
aggregates of different sizes and shapes. Another strategy
involves the use of hydrophilic-hydrophilic segments in
which one of the blocks changes its nature to hydrophobic
in response to an external stimulus as temperature and pH
[170, 171]. Due to remarkable development of knowledge
in the area of CRLP the number of monomers used in the
preparation of self-assembly structures is extremely vast.
Different strategies can be used to prepare micelle-like
entities, typically the core is hydrophobic and is responsible
for the phase transfer and sequestration of lipophilic
molecules, while the outer “corona” is responsible for the
stabilization of the structure in water [172].
There are several possibilities to incorporate therapeutic
molecules into micelles and vesicles, such as: hydrophobic/
hydrophilic interactions, electrostatic attractions, hydrogen
bonding and/or covalent bonds.
Using, for instance pH, sensitive polymers, it is possible
to synthesize block copolymers with precise smart poly-
mers that will self-assemble, and can be used as nano-
carriers for anti-cancer drugs, and therefore release the drug
when triggered by the acidic nature of most tumors
(5.8∼7.2), inflamed tumors, endosomal compartments or
specific organs according with the characteristic pH
(Table 8, in the previous section).
Recently, the CLRP methods turned possible the
synthesis of a large number of stimuli-responsive polymeric
systems, which led to the appearance of massive number of
publications about this subject. It is extremely difficult to
cover all contributions available for the different CRLP
techniques and because of that only the most relevant
publications will be considered, with the special focus on
ATRP. Some important references on RAFT technology are
also mentioned. Bioapplications of macromolecules pre-
pared by RAFT polymerization has been recently reviewed
in detail [173].
Temperature responsive polymers
The N-substituted acrylamide polymers are the most
commonly used thermo-responsive polymers. Some exam-
ples are presented in Fig. 30.
The most studied N-substituted acrylamide is the PNI-
PAAm mainly because it displays a LCST value (32°C) very
close to the human body temperature, and may therefore be
applied in the biomedical applications, e.g., stimulus
sensitive DDS. As mentioned before, the LCST value can
be tunned by changing the molecular weight, end function-
alities, adding hydrophilic and/or hydrophobic segments.
On this matter, the CLRP methods are a powerful tool to
synthesize precise NIPAAm based macrostructures with
controlled molecular weight, low polydispersity polymers,
complex architectures, and having at the same time stimuli-
responsive properties.
The first report on the controlled ATRP of PNIPAAm was
published in 2004 byMasci and co-authors [174]. The authors
proposed the synthesis in a mixture of dimethylformamide
(DMF)/water 50:50 (v/v) using a catalytic system of CuCl/
tris(2-dimethyl aminoethyl) amine (Me6TREN). Following
this work, several thermoresponsive copolymers had been
synthesized via ATRP. Li and co-authors [175] reported the
synthesis of biocompatible thermo-reponsive gelators based
Fig. 30 N-substituted acrylam-
ide polymers used to synthesize
thermo-responsive structures
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on ABA triblock (A-PNIPAAm and B—(poly(2-methacry-
loyloxyethyl phosphorylcholine) (PMPC)) using a bifunc-
tional initiator. Concerning ABC block copolymers, a doubly
thermoresponsive poly(phenylene oxide)(PPO)-PMPC-PNI-
PAAm triblock copolymer gelators was synthesized by
ATRP using a PPO-based macroinitiator [176]. The PPO
exhibit an LCST near 15°C, and the authors demonstrated
that for sufficiently long PPO blocks, the PPO-PMPC-
PNIPAAm block copolymer presented two separate thermal
transitions corresponding to micellization and gelation. The
development of different block copolymers having PPO and
PNIPAAm is particularly interesting, due to the presence of
these two transitions. Above 15°C the PPO becomes
hydrophobic leading to the formation of PPO-core micelles.
Above 32°C the PNIPAAm becomes hydrophobic resulting
in the formation of a micellar network (Fig. 31) [176].
In a very interesting contribution, Li and co-authors [177]
prepared temperature/pH-responsive core-shell-corona
micelles with different structures based on (poly(tert-butyl
acrylate) (PtBA)-co-poly(acrylic acid) (PAA))-PNIPAAm.
PtBA-b-PNIPAAm was firstly synthesized by sequential
ATRP followed by partial hydrolysis of PtBA segments. At
pH 5.8 and 25°C, the block copolymer self-assembled into
spherical core-shell micelles with hydrophobic PtBA seg-
ments as the core and hydrophilic PAA/PNIPAAm segments
as the mixed shell. Increasing temperature, core-shell micelles
are converted into core–shell–corona micelles with PtBA as
the core, collapsed PNIPAAm as the shell, and soluble PAA
as the corona. Decreasing pH at 25°C, PAA chains collapsed
onto the core resulting in core–shell–corona micelles with
PtBA as the core [177].
Self-assembly of poly(t-butyl acrylate-co-acrylic acid)-b-
poly(N-isopropylacrylamide) (P(rBA-co-AA)-b-PNI-
PAAm), which was obtained from part hydrolysis of
PtBA-b-PNIPAAm synthesized by sequential atom transfer
radical polymerization (ATRP) was studied. Thermo- and
pH-responsive core-shell-corona (CSC) micelles with dif-
ferent structures were formed from (PtBA-co-PAA)-b-
PNIPAAm in aqueous solution. At pH 5.8 and 25°C, the
block copolymer self-assembled into spherical core-shell
Fig. 31 a Reaction scheme reported by Li and co-authors for the
synthesis of PPO-PPMC-PNIPAAm triblock copolymer via ATRP; b
Schematic representation of aqueous solution behaviour of the PPO-
PMPC-PNIPAAm triblock copolymers: molecular dissolution at 5°C,
formation of PPO-core micelles between 10 and 20°C, and formation
of a micellar gel network above 31°C (adapted from [176])
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micelles with hydrophobic PtBA segments as the core,
hydrophilic PAA/PNIPAAm segments as the mixed shell.
Increasing temperatures, core-shell micelles converted into
CSC micelles with PtBA as the core, collapsed PNIPAAm
as the shell and soluble PAA as the corona. Moreover,
decreasing pH at 25°C, PAA chains collapsed onto the core
resulting in CSC micelles with PtBA as the core, PAA as
the shell and PNIPAAm as the corona.
The PNIPAAm was successfully polymerized by RAFT
using either benzyl dithiobenzoate or benzyl and cumyl
dithiovarbamates as chain transfer agents (CTAs) [178] in
1,4-dioxane at 60°C. There are several contributions in the
literature that describe the synthesis of PNIPAAm based
materials via RAFT polymerization [178–182].
The controlled polymerization of a polymer from a
biological structure is theoretically the more evident
method for the synthesis of bioconjugates. In this approach
the biomolecules are chemically modified with initiating
groups for CLRP and are subsequently used as macro-
initiators in the polymerization. Using modified biotin-
moieties, Hong and co-authors [183] reported the synthesis
of poly(NIPAAm-b-N-(2-hydroxypropyl) methacrylamide)
via RAFT method. This block copolymer is able to form a
coreshell nanostructure with biotin groups on the surface,
by changing the temperature (Fig. 32).
In the same line of research, Kulkarni and co-authors [184]
reported a very interesting example of post-modification of
PNIPAAm with a biotin derivative. The reported block
copolymer of biotin-terminated PNIPAAm-b-PAA was con-
jugated to streptavidin (SA) via the terminal biotin.
pH-responsive block copolymers
As referred before the pH-responsive polymers possess
ionizable pendant weak acidic or basic moieties attached to
the polymer backbone. Due to catalyst poisoning the
controlled polymerization of acidic monomers was prob-
lematic via ATRP [185]. In 1999, Armes and co-authors
[186] reported the “First example of the atom transfer
radical polymerisation of an acidic monomer” by using
methacrylic acid (MAA) in its sodium salt. This contribu-
tion represented a mark for the spread of the concept to
other acid monomers, as the sodium 4-vinylbenzoic acid
(VBA). Using the same approach, the synthesis of a wide
range of pH-stimulus polymers was finally possible.
Regarding basic monomers, Matyjaszewski and co-authors
reported the CLRP of 2-(dimethylamino)ethyl methacrylate
(DMAEMA) [187] using Cu(I)Br complexed with different
amine ligands, ethyl-2-bromoisobutyrate (EBiB) or 2-
bromopropionitrile (BPN) as the initiator in different
solvents. Shortly before, the block copolymers of
polystyrene-poly(2-(dimethylamino)ethyl methacrylate)
(PDMAEMA) were prepared by SFRP [188]. However,
the molecular weight of the PDMAEMA segment was not
controlled. The PDMAEMA is particularly interesting
because it exhibits both temperature and pH-responsive
behaviour. The pH-responsive copolymers containing poly-
base blocks, with pKa of 7.0–7.5, such as the tertiary
amine-based methacrylate polymers, PDMAEMA [189],
poly(N,N –diethyl aminoethyl methacrylate) (PDEAEMA)
[189, 190] and poly(2-(diisopropylamino)ethyl methacry-
late) (PDPAEMA) [190, 191] are among the most used
polymers [192]. Their pendant amine groups gain protons
under acidic conditions and release them under basic
conditions.
Amphiphilic AB block copolymers of DMAEMA with
methyl methacrylate (MMA), methyl acrylate (MA), or
styrene (St) have been synthesized by ATRP [193] using
well-defined poly(methyl methacrylate) (PMMA), poly
(methyl acrylate) (PMA), and polystyrene (PS) macro-
initiators. Different block copolymers containing different
lengths of PDMAEMA segments were reported by varying
the ration of DMAEMA and macroinitiators. ABA –
triblock copolymers of PDMAEMA-PMMA-PDMAEMA
were also reported by using difunctional PMMA macro-
initiator [193].
The polybase-based micelles were amply used as pH-
triggered drug carriers for delivery of several active substan-
ces, such as: chorambucil [194], anti-cancer taxomifen [195],
antiparasitic miltephosine [196] and dipyridamole [189].
Di- and tri-block copolymers of MAA and MMA were
reported via ATRP [197]. In aqueous solutions, the
polymers are water-soluble at high pH and the core-shell
micelle consists in the hydrophobic MMA core surrounded
Fig. 32 Schematic of the for-
mation of nano core-shell
structure from
P(NIPAAm-b-HPMA) with
biotin on the surface induced
by temperature (adapted from
[183])
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by hydrophilic MAA shell. P(MMA-b-MAA-b-MMA) with
longer MMA segment self-assembles via the closed
association mechanism through stronger self-entanglement
of MMA chains, whereas P(MMA-b-MAA-b-MMA) with
shorter MMA chain self-assembles via the open association
mechanism [198].
Dai and co-authors [199] studied the block copolymer-
ization of PMAA-b-PDEA through ATRP. At high pH
micelles were formed consisting of poly(N,N-diethylacry-
lamide) (PDEA) core and PMMA shell. However, at low
pH, unimers co-existed with micelles comprising PMMA
core and PDEA core.
The possibility to easily tailor the segment chain and
composition is of outstanding importance to the stringent
control over the self-assembly process. Ma and co-authors
[175] described the synthesis of biocompatible pH- responsive
ABA triblock copolymer based on A= 2-(diisopropylami-
noethyl methacrylate) (DPA) and B = 2-methacryloyloxyethyl
phosphorylcholine (MPC). The MPC can be used to produce
highly biocompatible surface coatings that exhibit remarkably
resistance to protein adsorption and bacterial adhesion [200].
Teoh and co-authors [201] reported the synthesis of
fullerene (C60) containing ampholytic block copolymer of
poly((methacrylic acid)-block-(2-(dimethylamino)ethyl
methacrylate))-block-C60 (P(MAA-b-DMAEMA)-b-C60)
by ATRP (Fig. 33).
The authors found that the amphiphilic mono-C60 end-
capped block copolymer showed enhanced solubility in
aqueous medium at room and elevated temperatures and at
low and high pH, but phase separates at intermediate pH
between 5.4 and 8.8. At pH 11 and 55°C the polymer
formed micelles and aggregates, whereas at the same
temperature but pH 3 the polymer formed unimers and
aggregates.
Armes and co-authors reported a novel zwitterionic poly
(4-vinylbenzoic acid-block-2-N-(morpholino)ethyl methac-
rylate) (P(VBA(63)-b-MEMA(123))) [202] diblock copol-
ymer synthesized via ATRP using protecting group
chemistry for the acidic residues (Fig. 34). VBA core
micelles were formed at pH below 6, while above pH 6 the
block copolymer dissolved unimers. Very interesting was
the fact that under alkakine media and in the presence of
salt (Na2S2O4) or at elevated temperature, well-defined
MEMA-core micelles were formed. The MEMA is a very
interesting polymer since it displays both pH and temper-
ature sensitive behaviour.
The core-shell micellar structures based on acidic-
containing copolymers were used as pH-triggered drug
carriers for delivery several drugs with different natures.
Star-shaped polymer containing ethyl methacrylate (hydro-
philic), tert-butyl methacrylate, poly(ethylene glycol)meth-
acrylate (hydrophilic) were synthesized by ATRP using a
Fig. 33 Synthetic scheme reported by Teoh and co-authors for synthesis of P(MAA102-b-DMAEMA67)-b-C60 (adapted from [201])
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four-armed multifunctional initiator [203]. The results
suggest that star-shaped with high molar ratio of hydro-
phobic monomers tend to form high molecular weight
aggregates in water. The system was used as potential
delivery system for the oral administration of hydrophobic
drugs (progesterone (PRG) was used as drug model) [203].
Sant and co-authors prepared diblock copolymers of PEG,
tert-butyl methacrylate, ethyl acrylate or n-butyl acrylate by
ATRP [204]. After the hydrolysis of the t-butyl groups all
the polymers exhibited pH-dependent aggregation behav-
iour and their critical aggregation concentration decreased
with the increase in the hydrophobic block length. The
stimuli-responsive system was designed for poorly water-
soluble model drugs (indomethacin (IND), fenofibrate
(FNB) and PRG). The results presented by the authors
indicate that supramolecular assemblies with high drug
loadings and pH-dependent release kinetics can potentially
enhance the oral bioavailability of poorly water-soluble
drugs [204]. Satturwar and co-authors synthesized block
copolymer poly(ethylene glycol) and t-butyl methacrylate,
iso-butyl acrylate, n-butyl acrylate or propyl methacrylate
by ATRP. Again, pH-sensibility was obtained by hydrolysis
of t-butyl groups. The model drug used was candesartan
cilexetil (CDN) and the results suggest that the pH-sensitive
micelles was triggered upon an increase in pH from 1.2 to
7.2 [205]. Tian and co-authors [206] attached PAA at the
ends of Pluronic P85 copolymer via ATRP to produce a
novel block copolymer PAA-b-P85-b-PAA.
The complex formation and drug loading were found to
be strongly depend on the PAA segment and pH. The
protonation of carboxyl groups in the PAA segment at pH<
7.2 reduced the binding sites of doxorubicin (DOX, water
soluble cationic drug) onto P85PAA chains, resulted in
diminished DOX uptake at low pH. The block copolymer
PAA-b-P85-b-PAA proved to be efficient in the complex-
ation of DOX and could be pH-triggered in an acidic
environment at pH 5.0. (Fig. 35)
The same research group reported a similar study with
Pluronic® F87 [207].
Using RAFT methods, McCormick and co-authors [208]
were the first to report RAFT stimuli responsive block
copolymers that undergo reversible micellization in aque-
ous solutions. The authors used dithioester-capped sodium
4-styrenesulfonate homopolymer as a macro-CTA to pre-
pare the block copolymer with sodium 4-vinylbenzoate in
aqueous media. The micelles hydrodynamic diameter
ranged from 18–38 nm. Other block copolymers with pH-
responsive behaviour were prepared by using RAFT agents,
such as: copolymers of sodium 2-acrylamido-2-methylpro-
panesulfonate (AMPS) and sodium 3-acrylamido-3-meth-
ylbutanoate (AMBA) [209]; AB diblock and AB statistical
block copolymer of AMPS and AMBA [210]; poly(sodium
2-(acrylamido)-2-methylpropanesulfonate-block-sodium 6-
acry lamidohexanoate ) (pNaAMPS-AaH) [209] ;
acryloamido-styrenic diblock copolymers AB (A-poly(N,
N-dimethylacrylamide) and B- N,Ndimethylvinylbenzyl-
amine (DMVBA)) [211]. Double responsive block copoly-
mers of PNIPAAm-b-PAA were synthesized in methanol
using 1-cyanoethyl-2-pyrrolidone-1-carbodithioate as
RAFT agent [212]. The authors demonstrated that the
solution behaviour was strongly dependent on the
hydrogen-bond interactions between NIPAAm and AA
Fig. 34 Schematic representa-
tion of the synthesis of
P(VAB63-b-MEMA123) reported
by Armes and co-authors
(adapted from [202])
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blocks. The block copolymers were sensitive to pH,
temperature, block length and solvents (Fig. 36) [212].
As it will be presented later, liposomes possess several
features that make these structures very interesting for drug
delivery purposes. Modified liposomes have shown to have
excellent pharmokinetic profiles for the delivery of several
structures such as nucleic acids, proteins and chemothera-
peutic agents [213]. However, these nanocarriers have low
stability and the lack of tunable triggers for drug release. In
order to overcome both problems, Lee and co-authors [213]
have proposed a very elegant strategy via a simple drop in
procedure using a cholesterol-functionalized PAA. The
active carboxylate groups are cross-linked with telechelic
2,2′-(ethylenedioxy)bis(ethylamine) linkers, resulting in
polymer-caged liposomes that are highly stable and have tunable
pH-sensitive responses (Fig. 37). The cholesterol-terminated
PAA was synthesized via nitroxide mediated polymerization
(NMP) of tert-butyl acrylate followed by acidolysis.
CLRP and “click chemistry”
The application of CLRP and “click chemistry” offers a robust
method to produce new polymers with tailor-made features
aiming to improve the biocompatibility and biodegradability
of the DDS. “Click chemistry” represents a philosophy
inspired by the simplicity and efficiency of the chemistry of
the mother Nature. The concept was introduced by Sharpless
and co-authors [214]. The main objective is to establish
straightforward and highly selective reaction systems to
synthesize precise structures. The most representative
reaction of “click chemistry” is the copper catalyzed
Huisgen 1,3 –dipolar cycloaddition of azides and terminal
alkynes [215, 216] (Fig. 38).
Since alkynes are poor 1,3-dipole acceptors in the absence
of a proper catalyst the reaction is fairly slow. In the presence
of copper (I) that can bind to terminal alkynes, the reaction
becomes extremely fast, regioselective and efficient. Another
important feature is the fact that the cooper catalyzed Huisgen
cycloaddition can be performed at room temperature in various
solvents and is tolerant to several functional groups [216]. The
combination of ATRP with “click chemistry” opens the door
to the creation of new range of materials through polymer
functionalization and macromolecular engineering. In these
works, most frequently, the ATRP polymers are transformed
into azides by nucleophilic substitution and subsequently
reaction with alkyne-functionalized molecules (Fig. 39).
Polypeptide-based rod-coil diblock copolymers (poly
(gamma-benzyl-L-glutamate) (PBLG)-PDMAEMA) were
Fig. 35 a Schematic representation of the complexation of P85PAA60/DOX behaviour at pH 3.87; b Schematic representation of the
complexation of P85PAA60/DOX behaviour at pH 7.2 (adapted from [206])
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synthesized via combination of ATRP and “click chemistry”.
PDMAEMA was synthesized by ATRP from alkyne- or
azide-functionalized initiators and coupled with the
corresponding azide-or alkyne- modified synthetic poly-
peptide prepared from ring-opening polymerization [217].
Degradable brushes of PHEMA-PDMAEMA were syn-
thesized via ATRP and “click chemistry” by Jiang and co-
authors [218]. The brushes were composed of backbone of
PHEMA onto which PDMAEMA was grafted via a hydro-
lysable linker. Both PDMAEMA and PHEMA were
synthesized by ATRP with controlled molecular weight
and narrow distributions. Click reaction between PHEMA
with alkyne side groups and the azide end group in the
PDMAEMA resulted in a high-molecular-weight polymer
composed of low-molecular-weight constituents via an
easily degradable carbonate ester linker (Fig. 40). The
degradable brushes were able to transfect cells efficiently in
the presence of the endosomal-disrupting INF-7 peptide.
Miniaturization of DDS
Micro- and nanoparticles
Drug delivery systems often use polymeric carriers that act
as “drug transporters”. The use of a carrier allows
Fig. 36 Modes of aggregate
formation for block copolymers
PNIPAAm-b-PAA in
aqueous solution in dependence
of pH and temperature
(adapted from [212])
Fig. 37 Drug release from a
pH-responsive liposome with a
PAA crosslinked shell (adapted
from [213])
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overcoming some problems associated with the develop-
ment and application of new drugs. Despite the new fact
that new biologically active molecules are being discovered
constantly, some of them present serious limitations to their
use such as: rapid drug elimination; poor solubility and
biodistribution which can compromise interaction of drug
and site of action; low solubility at physiological pH [219]
and insufficient cellular uptake [220]. The use of a DDS
can be a very effective way of overcoming these barriers.
However, when DDS are concerned, both design and
engineering are to be considered in order to optimize drug
efficiency as well as reduce their side-effects [221].
Particulate systems as DDS can be prepared using
different types of materials like polymers, lipids or
peptides. Particles prepared from either natural or synthetic
polymers have been extensively investigated to be applied
as DDS. Their synthesis can be achieved from different
techniques [222]. Among them, are emulsion polymeriza-
tion, solvent evaporation, ionic gelation, self-assembly,
nanoprecipitation and supercritical fluid technology [223].
Within particles, two different categories can be distin-
guished: spheres and capsules. The first type refers to
spherical particles composed of homogeneous mixtures of
active agent and polymer while the second is applied when
the particle presents a core (where the active agent is
placed) that is delimited by a different material (usually the
polymer). The core may present itself in distinct forms and
states from solid to even gas. Several active agent domains
may be found inside the capsule core. Some potential
particles morphologies are presented in Fig. 41.
Another parameter used in particles classification refers
to their size. Therefore, two categories are considered:
micro- and nanoparticles. The distinction between both
classes is often confusing and even polemic. Lately, the
most accepted classification reports that particles up to
100 nm are considered nanoparticles while the ones from
1 µm up to 1,000 µm are classified as microparticles [225].
However, because of their small size, both can be injected
directly into the systemic circulation or a certain compart-
ment of the body. This process allows a high local drug
concentration and can also be adapted to alternative
administration routes such as inhalation or topical admin-
istration if properly sustained. They are extremely stable
allowing the encapsulation of both hydrophobic and
hydrophilic drugs. However, the most explored ability of
the particles during last years is the possibility of directing
them to specific places where drug is to be delivered by
using targeting strategies. Several factors can influence
drug release from both micro- and nanoparticles, namely
the nature of the carried drug (including charge and even
size), particle size and composition and even surrounding
conditions such as pH and temperature [226].
Size difference between micro- and nanoparticles,
implies differences in their performance. This means that
each system presents its own advantages as well as
limitations. Mathematically speaking, the surface area/
volume ratio is inversely proportional to the radius of the
sphere. This means that, when smaller particles are formed,
drug diffusion from the particles surface occurs in higher
proportions [227]. Due to the increased surface area, water
Fig. 38 1,3-Dipolar cycloaddi-
tion between azides
and alkynes
Fig. 39 Schematic representa-
tion of the transformation of a
bromide chain end into
azide and subsequent reaction
alkyne-functionalized molecules
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diffuses easier towards inside smaller particles causing
higher drug release kinetics. This enlarged drug release rate
does not always consist on a system advantage since is
often accompanied by initial burst release.
Micro- and nanoparticles performance also differ in
terms of their fate after injection, their ability to cross
barriers and enter cells as well as tissue reaction [227].
While microparticles are likely to stay in place after
injection in tissues, nanoparticles tend to clear from
injection place after some time. Kohane and co-authors
injected several concentrations of both micro- and nano-
particles in the abdominal cavity of mice [228]. They
observed that while microparticles could still be seen in
injection site after 2 weeks, the same did not happen to the
nanoparticles.
The problem associated with size is even more important
when intravenous injection is used. When microparticles
are too large, they may block blood flow through vessels
with the same caliber as their diameter. This can result in
strokes at end organs. However, microparticles up to 20 µm
are widely applied in DDS design for inhalation applica-
tions [229].
Fig. 40 Schematic representation of the strategy reported by [218] to
prepare degradable brushes of PHEMA-PDMAEMA. A ATRP of
DMAEMA from 2-bromo-isobutyric acid 3-azidopropylester (BiBAP
in Dichlorobenzene (DCB); b PHEMA with side chain of alkynes; c
“click chemistry” to form degradable brushed PHEMA–PDMAEMA
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Because of its very small size (lower than cells diameter,
Fig. 42) nanoparticles can easily cross biologic barriers as
well as easily enter all type of cells. Contrarily, micro-
particles, can only be incorporated by cells with phagocytic
capacity [230].
Nanoparticle-based DDS were primarily developed as
carriers for vaccines and cancer chemotherapy agents [231]
but have so far proved to comprise considerable potential for
treatment of several diseases [232]. In fact, nano-DDS can be
applied in the treatment of different diseases such as cancer
[233], AIDS (acquired immune deficiency syndrome) [234],
diabetes [235], malaria [236], tuberculosis [237] and even
prion disease [238]. This broad range of application is
directly related to the possibility of targeting nanoparticles
and therefore directing them to a specific organ.
Liposomes
Liposomes were reported, for the first time, during the
1960s and their clinical use was approved in the mid-1990s.
These self-assembled vesicles consist of an aqueous core
domain entrapped by a lipidic bilayer [239].
The formation of liposomes is related to hydrophilic/
hydrophobic interaction between lipid/lipid and lipid/water
molecules. In aqueous medium, lipids rearrange them-
selves, first, as bilayer sheets, with the headgroup of the
lipid (hydrophilic) facing the water phase while the
hydrocarbon chains (hydrophobic) are forced to face each
other. Immediately afterwards, the formation of liposomes
occurs (Fig. 43) [240, 241].
Liposomes can be classified according to their lamellar-
ity (number of bilayer membranes) and size (Fig. 44) in
[239, 240]: small unilamellar vesicle (SUVs) (∼0.02 μm to
∼0.2 μm), large unilamellar vesicles (LUVs) (∼0.2 μm to
∼1 μm), giant unilamellar vesicles (GUVs) (>1 μm) and
multilamellar vesicles (MLVs) (> 0.1 μm).
The simplest method for the preparation of liposomes is the
thin-film hydrationmethod, which yieldsmostlyMLVs. Other
methods, like reverse-phase evaporation technique and
solvent injection are also used and produce mostly LUVs.
Preparations containingMLVs or LUVs can, subsequently, be
sonicated or extruded in order to give SUVs [239, 240].
In the thin-film hydration method, a dried lipidic film is
hydrated in an aqueous buffer solution, at a temperature
above the transition temperature (temperature at which a
lipid passes from the gel state to a liquid state) of the lipids.
As stated above, this method originates preferentially
MLVs, with high heterogeneity in size, size distribution
and lamellarity. In solvent injection method, an ethanolic or
etheric solution of lipids is slowly injected into an aqueous
phase, forming unilamellar liposomes. The vesicles
obtained by this method present a well-defined size
distribution and high encapsulation efficiency. Removal of
residual solvent is done by dialysis against distilled water
[240]. Figure 45 presents the different methods that can be
used in the liposomes preparation.
Recently, due to their biocompatibility, non-immunogenicity,
non-toxicity and ability of entrapping both hydrophilic and
hydrophobic compounds, liposomes emerged as attractive
materials for the development of DDS (Fig. 46) [239, 242].
Furthermore, a wide spectrum of properties for liposomes can
be obtained by just varying the lipid (natural or synthetic) or
lipid composition used in their preparation. Chemical surface
modification of liposomes is also possible. The incorporation
of specific molecules or macromolecules can enhance the
interaction of liposome with a target site [243].
Although liposomes are promising carriers for drug
delivery, they have shown low transfection efficiency and
Fig. 42 Sizes of nanoparticles
compared with other biological
entities
Fig. 41 Potential particles mor-
phologies (adapted from [224])
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low stability after intravenous injection, due to absorption
of plasma lipoproteins at the liposome surface. They also
tend to be rapidly cleared from systemic circulation through
reticuloendothelial system (RES) in living cells [244, 245].
In order to increase long-term stability of the liposome in
the blood stream, it is necessary to alter some of the
vesicles properties, namely particle size, surface charge and
fluidity. Sterical stabilization of liposomes can be achieved
by incorporating compounds bearing hydrophilic groups in
lipidic bilayer [239, 245]. One of the most widely used
method for liposome stabilization, with consequent en-
hancement of circulation time, is the incorporation of a poly
(ethylene glycol) conjugated phosphatidylethanolamine
(PEG-PE) into its structure [246–248].
An additional stabilizing effect of the liposome bilayer
can be achieved by including cholesterol in the formulation.
Cholesterol is used as a membrane sealer, minimizing
bilayers permeability and providing mechanical and cohe-
sive strength [244, 249].
A possible strategy to increase the usefulness of lip-
osomes in the drug delivery field is to prepare functional
liposomes that can response to changes, for example, in pH
or temperature of surrounding medium. These are useful for
site-specific and/or cytoplasmatic drug delivery [250]. The
most effective method for that purpose is the incorporation
of functional polymers in the liposome. These polymers
should be amphiphilic, with the polymers hydrophobic part
acting as an anchor to the liposome surface. The stimulus-
induced conformational changes of the polymers induce a
partial or total arrangement of the liposome structure, which
is believed to be responsible for the release of drugs from
the liposome [251].
Temperature sensitive liposomes are prepared from
polymers that exhibit a LCST in aqueous medium. These
kinds of polymers are highly hydrophilic below the LCST,
but become hydrophobic above this temperature value.
Therefore, incorporation of the polymer in the liposome is
expected to destabilize the liposomal structure when
temperature is raised above the LCST. Their copolymeri-
zation with other monomers, with varying hydrophilicity/
hydrophobicity, enables the adjustment of the LCST to a
desired temperature [252, 253]. Poly(N-isopropylacrylamide),
that exhibits a LCST around 32°C, is the most widely
used polymer for the preparation of temperature sensitive
liposomes.
Takagishi and co-authors prepared phosphatidylcholine
(PC) liposomes thermal-responsive, by coating them with a
NIPAAm-octadecylacrylate (ODA) copolymer [254]. In
other study, Takagishi and co-authors used a copolymer of
NIPAAm and N,N-didodecylacrylamide (NDDAAm) to
coat a PE based liposome. NDDAAm presents along acyl
chain, which allows the copolymer to be tightly bound to
the liposome. In addition to hydrophobic interactions, the
interaction between the membrane and the copolymer can
be enhanced by the establishment of hydrogen bonds.
During this work, it was shown that the incorporation of PE
in liposome formulation is important for the development
of more efficient drug delivery systems [252]. Han and co-
authors studied the release of doxorubicin from liposomes
modified with poly(NIPAAm-co-acrylamide) P(NIPAAm-
AAm) and poly(ethylene glycol). They showed that
incorporation of the copolymer and poly(ethylene glycol)
enhanced drug release from liposomes and reduced protein
adsorption in serum [255].
Fig. 43 Schematic representa-
tion of the liposomes’ formation
Fig. 44 Schematic representa-
tion of the different types of
liposomes, depending on their
size and number of lamellae
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Recently, Paasonen and co-authors prepared a temper-
ature sensitive PC and PE based liposomes using poly(N-
(2-hydroxypropyl) methacrylamide) mono/dilactate. The
copolymer was functionalized with a cholesterol moiety
that acts as an anchor to the lipidic vesicle. When
compared with the NIPAAm based copolymers, this kind
of copolymer presents the advantage of being biodegrad-
able, with a LCST ranging from 13 to 65°C [242].
The sensization of liposomes to pH by incorporation of a
pH-sensitive polymer was reported by Tirrel and co-authors, in
the early 80’s. They showed that the attachment of poly(2-ethyl
acrylic acid) (PEAA) onto liposome surface gave pH-sensitive
content release properties. This polymer interacts with lipidic
membrane in a pH dependent manner. At mildly acidic
conditions, in high concentrations, PEAA induces micelization
of the membranes, whereas at low concentrations, it perme-
abilizes them [256]. The pH at which permeabilization occurs
can be modulated by adjusting the polymer molecular weight
or substituting PEAA by another acrylic acid derivative [257].
Succinylated poly(glycidol) (SucPG), that present –OH
and –COOH groups on the side chain, can also be used to
prepare pH-sensitive liposomes [257]. Kono and co-authors
have incorporated (SucPG) bearing long alkyl chains in the
structure of PC vesicles [258]. This complex is stable at
neutral pH, being destabilized under mildly acidic con-
ditions. It was shown that it could deliver calcein into the
cytosol through fusion with endosome/lysosome mem-
branes. It is believed that the mechanism responsible for
the destabilization of liposome, when in contact with
SucPG, is related to two phenomena: the hydrophobic
interaction of SucPG backbone with lipid membrane and
hydrogen bond formation between polymer carboxyl groups
and phosphate groups of the phospholipid membrane [257].
More recently, Sakaguchi and co-authors demonstrated that
pH sensization of eggPC was enhanced with increasing side-
chain hydrophobicity of poly(glycidol) derivatives [259]. The
introduction of a titratable comonomer in the structure of
hydrophobically-modified PNIPAAm can make the polymer
pH-responsive. Leroux and co-authors have prepared a pH-
sensitive liposome from eggPC/cholesterol, by incorporating
a copolymer of NIPAAm, methacrylic acid and ODA into the
liposomes lipidic layer [260].
Recently, Cho and co-authors prepared a pH-sensitive
system composed of poly(methacrylic acid-co-stearyl meth-
acrylate), PC and cholesterol. The complex was stable at pH
above 6, becoming slightly disorganizedwhen pHwas 5 [251].
All the systems above referred are commonly known as
polymer incorporated liposomes (PIL). Although they are able
to respond to temperature or pH changes of the medium, it is
known that they can dissociate from the liposome surface,
returning them to the unstable state. This is related with the
chain length and/or saturation degree of the anchor.
Cell and gene therapy
Cell therapy
Due to the need of increasing the level of drugs safety,
capable of reaching the target with minimal side-effects
Fig. 46 Localization of hydro-
philic and hydrophobic drugs
within the liposome
Fig. 45 Different methods used
in the liposomes preparation
(adapted from [240])
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emerged a great interest of cell therapy in the area of DDS.
The bio-distribution of pharmaceuticals throughout the
body has been reported as one of the main problems
associated with systemic drug delivery administration. This
leads to indiscriminated distribution requiring the use of a
excessive concentration of drug to achieve the desired
therapeutic level. This means that the drug is wasted in
normal tissues and has a subsequently limited therapeutic
efficacy. Thus, the ideal drug is the one that has
pharmacological activity only at target site, using concen-
trations as low as possible and without negative effects on
non-target compartments [261–263].
Cell-based delivery systems have been referred as the
nearer to ideal system for delivery of drugs. Cells are
capable of delivering drugs in response to an external
stimulus, which is highly advantageous to maintain
homeostasis for patients suffering from chronic diseases
[263]. These systems can be divided into two categories:
cells capable of expressing pharmaceutically relevant
agents (e.g., cytosine deaminase-expressing neural stem/
progenitor cells upon systemic 5-fluorocytosine adminis-
tration) [264] and cell carriers that can be loaded with drugs
or therapeutics. They can release the drug content in
circulation or at selected sites or even could target the drug
to other relevant cells in the body. Cell carriers investigated
include so far animal and bacterial cells [261].
Stem cells
Stem cells are characterized by having a prolonged self-
renewal capacity and the ability to differentiate into mature
stages and different tissue types by asymmetric replication
[265–267]. Therefore, it is essential to deeply know,
understand and identify cells differentiation and growth in
order to safely direct this knowledge towards clinical
applications [268].
Stem cells can be isolated from various sources, such as
a bone marrow, umbilical cord blood, peripheral blood,
adipose tissue, skin and hair follicules [267, 269–274].
Stem cells can be delivered through intravenous infu-
sion, intra-arterial infusion, direct implantation, intrathecal
infusion and also biomaterial implantation (engineered
scaffolding constructs) [263]. Despite the diversity of
delivery mechanisms, it has been reported that cells directly
injected into the body experienced less than desired
therapeutic efficacies for many reasons, including rapid
decrease in cell viability and immune rejection. Entrapped
cells into biomaterials has shown promising results for
reducing immune response and increasing efficacy and
viability of transplanted cells [262].
Biomaterials support for stem cells
Stem cells are implanted in the host organism seeded in
polymeric matrix that is design to work as a scaffold.
Scaffolds can be modified to mimic extracellular matrix
(ECM) and promote the attachment, growth and differen-
tiation of cells. After implantation, they may remain locally
obtaining long-term delivery or migrate to surrounding
tissues [275].
Scaffold design and materials must present certain
characteristics including: capacity for delivery without loss
of function, adequate cellular adhesion and influence cell
differentiation down desired cell lineages via mechanical or
chemical interaction with support matrix [263]. Table 9
presents some polymers used in supports for stem cells
applications.
The interaction between polymer scaffolds and cells is
crucial. It can be regulated by controlling specific ligand–
receptor interactions, physical properties of the scaffolds
(e.g., mechanical properties and degradation rate), and
release of incorporated molecules such as growth factors
or deoxyribonucleic acid (DNA) from the scaffolds
[275]. Analogous compounds or identical to adhesion
molecules (CAMs), such as integrins and cadherins,
naturally present at ECM must be added to the scaffold.
These molecules interact with proteins such as fibronectin
and vitronectin and enhance cell adhesion [263, 275].
Table 9 Examples of biomaterials used to improve cell-based drug delivery
Biomaterial Cell type Cell-secreted protein Reference
Poly(ethylene glycol) Islet cells Insulin [276–278]
Hyaluronic Acid Fibroblasts and embryonic stem cells – [279]
Sodium Alginate Osteoblasts – [280]
Fibroblasts – [281]
Fibroblasts Vascular endothelial growth factor [282]
Islet cells Insulin [283, 284]
Polyethersulfone Engineered kidney cells Ciliary neurotrophic factor [285]
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The influence of the entrapment process as well as the
material immunogenicity, porosity, and stiffness are impor-
tant factors in improving cell viability, cell function and
subsequent therapeutic efficacy, both in vitro and in vivo
[262].
Differentiated cells
Although most of research in DDS has been focused on
stem cells, mature cells (leukocytes, hepatocytes, plate-
lets, erythrocytes, islet cells, among others) can also be
used [286]. For example, many cells, such as ovary
cells, kidney cells, myoblasts, and fibroblasts, have been
genetically engineered to secrete specific therapeutic
proteins [262]. The most extensively studied are macro-
phages and erythrocytes.
Macrophages Macrophages are differentiated cells of the
immune system that are able to phagocytize microorgan-
isms, nanoparticulate materials and soluble compounds.
Mainly because of the phagocytosis phenomenon, macro-
phages have been considered as cell targets for selective
delivery of drugs using nanoparticles as well as cell carriers
for the delivery of therapeutic agents. This approach
requires that macrophages should be adoptively transferred
to the recipient after ex vivo loading with nanoparticles
formulated drugs and/or contrasting agents [287, 288]. The
majority of these macrophages (74-81%) are immediately
sequestered in the liver and in the spleen (13–18%) [287],
suggesting that they are more appropriate as a targeting
system than as a drug delivery system [261].
Erythrocytes Human red blood cells (RBCs) or erythro-
cytes, the most common cells of blood, are responsible for
oxygen transport and have a typical biconcave shape.
RBCs compared to other delivery systems have some
unique features making them not only natural, safe and
abundant carriers but, being endowed with enzymes
involved in bioconversion reactions, also active bioreac-
tors. RBCs are safe carriers that persist in circulation for
months and can release active pharmacological agents in
circulation for an equivalent period. RBCs permit to have a
low and constant drug concentration in blood that once
specifically selected can be therapeutically efficient with-
out side-effects [261, 286].
The erythrocytes constitute potential biocompatible
carriers for different bioactive substances, including protein
drugs, as well as conventional therapeutics. The main
features of using erythrocytes as a drug delivery system are
the following [261, 286, 289]:
– complete biodegradability without generation of toxic
products;
– high biocompatibility (especially when autologous
erythrocytes are employed);
– easily handled ex vivo by means of several techniques
for the encapsulation of different molecules, after
which one can obtain loaded erythrocytes with mor-
phological, immunological and biochemical properties
similar to those native cells;
– large volume available for the encapsulation drugs due
to lack of nucleus and other organelles;
– protection of encapsulated substance from premature
inactivation and degradation by endogenous factors
and, at same time, the organism against the toxic
effects of the drugs thus avoiding immunological
reactions;
– wide variety of compounds can be entrapped, even
peptides of high molecular weight;
– longer life-span in circulation (approximately 120 days);
– could act as bioreactors due to the presence of several
enzymatic activities that can turn a loaded prodrug into
the active drug itself;
– can use as a selective targeting of drugs directly to
macrophages without affecting the non-targeted com-
partments. After their natural life-span in systemic
circulation, the senescent RBCs are recognized by the
cells of the reticuloendothelial system and removed
from circulation to be destroyed.
The first clinical applications of RBCs as carriers were in
enzyme replacement therapy by Beutler and co-authors
who entrapped placental glucocerebrosidase into RBCs for
a selective delivery to macrophages [290].
Some other active substances that have been encapsu-
lated into red bloods cells include, toxins, peptides,
glutathione, antisense PNA, glucocorticoid analogues and
nucleoside/nucleotide analogues [261].
More recently several methods have been developed to
couple molecules of interest to RBCs for their in vivo
applications. The biotinylation of RBCs can be used to
encapsulate drugs or contrasting agents, normally, fluo-
rescent agents and/or superparamagnetic nanoparticles
[261, 286].
RBCs have been used for therapeutic applications: in
amino acid-based biopharmaceuticals (peptides and
peptidomimetics (enalaprilat, glutathione, dermaseptin
S4, listeriolysin, ubiquitin analogue), proteins (insulin,
erythropoeietin, interleukin-2, interleukin-3, interferon α-
2b), therapeutic enzymes (for example, β-galactosidase,
β-glucosidase, fumarase, glyceraldehydes 3-phosphate
dehydrogenase, etc); nucleic acid-based biopharmaceut-
icals (nucleosides, nucleotides and their analogues); and
immunogenic biopharmaceuticals (model antigens, bac-
terial toxoids, viral subunit vaccines, cancer vaccines)
[286].
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Gene therapy
Gene therapy can be defined as the transfer of genetic material,
a functional gene or DNA/ribonucleic acid (RNA) fragment
into specific cells to elicit a desired therapeutic phenotype in
order to reduce symptoms or treat human diseases [291].
There are two categories of somatic cell gene therapy,
according to genetic material delivery method, ex vivo or in
vivo. Ex vivo approach involves tissue biopsy, followed by
cells. Finally, modified cells are returned to the body. In vivo
approach consists in direct application of genetic material
into cells, e.g., direct tissue injection or modification of
culture cells for posterior implantation [292, 293]. These
therapies have an ample potential and have been heavily
investigated during the past 30 years. The first clinical trial
with gene therapy was initiated in 1990, and involved two
infants suffering from a form of severe combined immuno-
deficiency (SCID) resulting from adenosine deaminase
(ADA) deficiency. However, it took until April 2000 before
the first clinical success was reported [293, 294].
The success of gene therapy is highly dependent on the
development of a vector or vehicle that can selectively and
efficiently deliver the genetic material to target cells with
minimal toxicity [295, 296]. An ideal gene delivery vector
should be effective, specific, long lasting and safe. Vectors
can be generally categorized into viral and non-viral vectors.
Viruses carry and express modificated genes into host cells.
They are used in the majority of clinical trials and are often
the most efficient vectors. However they often initiate
immune responses, are limited in size of genetic material
they can carry, are difficult to produce and purify and exhibit
limited target-cell specificity (or often nonspecifity). More-
over non-viral vectors as cationic polymers have the potential
to be non toxic and nonimmunogenic, are chemically and
physically stable, are relatively easy to produce in large
quantities and can be targeted to desired cell types [267, 291].
There are two main types of viral vectors that transfer
foreign genetic information into cells: simple capsid virions
(the genetic material is inside a proteinaceous shell) like
recombinant adenovirus or adeno-associated virus (AAV) and
viruses with enveloped virions (the capsid is surrounded by a
lipid bilayer envelope) which include retrovirus, lentivirus,
alphavirus and herpes virus (Fig. 47). Viral vectors are
distinguished essentially by their size and transgene capacity,
target (efficiency and specifity with which the viral vector
infects the target cells), performance, duration of required
expression, immunitary response and safety [297, 298]. All
of these characteristics must be taken into account when a
viral vector is chosen in order to achieve better results.
Viral vectors are in a prominent position in strategies for
gene therapy essentially because of their high delivery and
transfection efficiency’s. Adenovirus (a double-stranded
DNA virus) is the vector most widely used in gene therapy
(24%), followed by retrovirus (20.9%) (single-stranded
RNA viruses that replicate through a DNA intermediate)
[299]. Adeno-associated viruses (single-stranded, non-
enveloped DNA viruses) represent only 4.3% of vectors
used in gene therapy clinical trials. Although viruses are
efficient in transducing cells, its production however, is
time and cost consuming and it is important to take into
Fig. 47 Two different approaches
of virus entering the cell, simple
capsid (a) and enveloped virions
(b) (adapted from [293, 297])
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account the risk of local or systemic infections [267]. Due to
adverse events in past clinical trials, the safety issue of gene
vector became a major concern that has hindered the advance
of gene therapy. Consequently the use of non-viral vectors in
clinical trials in recent years is increasing mainly due to their
reduced immunotoxicity and side-effects [296, 300, 301].
The simplest approach to non-viral delivery systems is
inducing gene expression by direct gene transfer (intra tissue
injection) with naked plasmid DNA (‘naked’ DNA). ‘Naked’
DNA are very specific and can promote long lasting gene
expression [296]. It is the third most used vector in gene
therapy clinical trials [301]. Recent advances improved the
precision and reproducibility of this approach using a
computer-controlled catheter guided injection device [302].
Moreover, intratracheal and intravenous administrations
normally requires the use of a delivery vector or vehicle. A
variety of non viral delivery methods for gene therapy with
potential for clinical trials are currently available. The gene
transfer systems most extensively studied are the cationic-
lipid and polymer-based systems [295, 303–306]. These
include cationic lipids or polymers, liposomes [307–310],
and nanoparticles [311–313]. In most cases, these vectors
have net positive charge, which contributes to both complex
formation with polyanionic nucleic acid and interaction with
negatively charged cell membrane [314, 315].
As mentioned before, liposomes consist of a phospho-
lipid bilayer vesicle entrapping an aqueous domain. They
are particles with stable physicochemical properties. Lip-
oplexes, moreover, are cationic lipid/DNA complexes,
spontaneously formed via interaction of positively charged
lipids and negatively charged nucleic acids and therefore
are unstable particles and should be prepared immediately
before use [316, 317]. The first description of a successful
in vitro transfection with cationic lipid was reported by
Felgner and co-authors in 1987 [318]. In following years,
many progress were made in this area. Surface modified
lipid-DNA nanoparticles are recent strategies for delivering
siRNA to specific tissues in vivo [319]. There are some
cationic lipids for genetic material delivery commercial
available, like Lipofectin®, RNAiFect™, Oligofectamine™,
Lipofectamine™ and TransIT® [314].
Nanoparticles have great potential as a strategy for
gene therapy. They meet the majority of discussed
characteristics for a successful vector. As mentioned
before there are many different formulations of nano-
particles. Nanoparticles and complexes polymer-genetic
material should be <100 nm to reduce renal excretion and
to be captured by cells [314, 320]. Typically, in gene
therapy, a segment of DNA or RNA (circular or linear) is
compacted with a policationic polymer. These particles
enter the cell via endocitosis and/or macropinocytosis and
rapidly transfficked to the nucleolus. In many cases
expression levels are superior that those observed after
treatment with naked plasmid DNA [305]. The success of
this vector is directly associated with nanoparticle formu-
lation, size or electric charge. Nanoparticles can be stably
stored under a variety of conditions and concentrations (up
to 12 mg/ml of DNA). They are tolerant of a wide range of
temperatures, salt concentrations and pH and they tend to
protect their genetic material from enzyme degradation
(deoxyribonuclease or ribonuclease). Polyethyleneimine
(PEI) has been widely tested for DNA, oligonucleotide
and siRNA delivery [314, 321, 322].
Non-viral vectors generally are superior to viral vectors
in safety, due to low risk of infection [296]. The simplicity
of use and the possibility of large-scale production is also
advantageous [295]. Different strategies are now being
developed to improve the non viral vector efficiency.
RNAi: Novel gene therapy approach
RNA interference (RNAi) was discovered by Fire and co-
authors in 1998 [323]. This discovery revolutionized
biological research. In 2006, the Nobel Prize in Physiology
or Medicine was attributed to Andrew Z. Fire and Craig C.
Mello for their discovery of RNA interference-gene
silencing by double-stranded RNA. RNAi is a natural
process through which expression of a targeted gene can be
knocked down with high specificity and selectivity [324]. It
plays an important role in the regulation of gene expression.
With this potential therapeutic application, it is now
possible to create small inhibitory RNA molecules, intro-
Cell transplantation Gene therapy
They can grow in culture indefinitely
(they are easy to maintain)
They can be deployed directly on the site
(e.g., the brain can pass the blood brain barrier)
They are multipotent (forming various types of cells) They are easily transfected with therapeutic
genes, may express more than one gene of
interest
The presence of viruses/diseases can be
analyzed in culture
They assume the phenotype of neighboring
cells after transplantation
They have a correct implementation in the host
tissue, allowing gene transcription
(proteic expression)They have the capacity to migrate after transplantation
They produce factors that contribute to tissue repair
Table 10 Main characteristics
of stem cells for use in thera-
peutic cell transplants and as
vehicle for gene therapy
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duce them into specific cells and inhibit expression of a
disease gene or block a destructive pathway [325, 326].
RNAi is a potent and specific gene silencing event in
which small interfering RNA degrades target mRNA which
has a complementary sequence to the siRNA [327]. siRNA
has, as convenient, specific and potent gene silencing effect
compared with conventional techniques such as antisense
oligodeoxynucleotides and homologous recombination-
based knockout strategies [324, 328, 329].
Gene therapy can be applied in many different diseases
including cancer, neurodegenerative diseases, muscular
dystrophy, immunologic diseases, blood diseases, among
others [297, 324, 330–333]. However, the easier choices for
gene therapy are the monogenic loss of function diseases,
associated with one gene mutation that results in loss of
gene function in a specific tissue. Gene therapy with RNAi
is a potential therapy for human diseases including human
genetic and acquired disorders such as cancer and viral
infections [334, 335]. Actually, cancer is the disease with
more developments in gene therapy, about 64,6% of all
research worldwide activity, followed by cardiovascular
diseases (8.9%), monogenic diseases (8.1%) and infectious
diseases (7.9%) [300, 301]. The future challenges are those
that optimize the individualized vector according to each
clinical setting.
A recent clinical possibility is to provide long-term
phenotypic correction by genetic modification of stem cells
in vitro before transplantation. Different cells have been
transduced with particular genes using different types of
vectors [261, 336]. The main characteristics of stem cells
for use in therapeutic cell transplants are schematically
shown in Table 10.
Gene and cell therapies have been widely developed in
recent years. Much has been done, but much still remains
to be done. Table 11 presents some other pathologies that
may profit in a near future from this top of the art
technology.
Conclusion and outlook
As the pathological and physiological mechanisms of
disease come more in focuse, a design of more effective
controlled release delivery systems becomes a greater
challenge. The development of new polymers more suitable
as biomaterials allows their extensive application in
delivery device construction, drug targeting as well as gene
and protein delivery. Also, the possibility of designing more
compact systems, such as micro- and nanoparticles makes
polymers a highly attractive field of research. More
recently, the advances in CLRP of several monomers that
lead to stimuli-responsive polymers and hydrogels open
several options that, in years to come, will allow a new and
more effective generation of DDS to arise.
Table 11 Some examples of gene and cell therapy applications
Pathology References
Pain [337]
Acute and chronic wounds [267]
Traumatic brain injury [263]
Diabetes [262]
Huntigton disease [262]
Parkinson disease [262, 338, 339]
Ischemia [262]
Bone defect [262, 336]
Cancer [340–342]
Muscular dystrophy [268]
Heart disease [343]
Fig. 48 Interrelationship of
DDS, pharmaceutical industry
and biotechnology (adapted
from [3])
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Biodistribution, stability, solubility, targeting, immuno-
genicity can be altered rationally designing macromolecules
synthesized by CLRP methods. The combination of these
methods and “click chemistry” present significant opportu-
nities for the design and synthesis of advanced macro-
molecules for DDS. It is predictable the appearance of new
high efficient macrostructures for DDS in a near future.
DDS technology has emerged as an unquestionable
interdisciplinary science aimed at advanced healthcare.
Recent technological breakthroughs in drug discovery
and development have resulted in novel therapeutics for
targeted prevention and individualized therapies potentially
leading to ultimate improvement of life quality of patients
treated. These innovations have been accomplished by
increasing interest (and consequently investments) in the
research field by pharmaceutical companies. In fact, drug
delivery technologies have become one of the major players
in biopharmaceutical industry. Multidisciplinary interaction
between drug delivery systems, pharmaceutical industry
and biotechnologies is summarized as represented in
Fig. 48.
However, and despite the understandable interest from
pharmaceutical industries in these devices, some new
advances are still to come. Most of recent research in
DDS is focused on developing new materials and prepara-
tion of responsive polymers with specific macro/micro-
structure and chemical profile. Special attention is being
paid to the design of copolymers with hydrophilic/hydro-
phobic segments, the synthesis of star shaped polymers and
dendrimes as nanocarriers for bioactive compounds as well
as the synthesis of bioconjugates. The medicine of future is
treated in a personalized way in accordance with the
individual parameters. By this concept it is predictable the
appearance of new effective tailor-made DDS, resulting
from knowledge of interdisciplinary research creating
personalized medical solutions.
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